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Stra13 and Sharp-1 are basic helix-loop-helix (bHLH) transcription factors 
expressed in many cell types during embryonic development as well as in 
adult tissues. They are involved in various biological functions such as cellular 
growth arrest, senescence, differentiation and apoptosis. However, the 
mechanisms by which their functions are regulated remain unclear.  
Post-translational modifications of proteins play an important role in the 
functional regulation of proteins. Small ubiquitin-like modifiers (SUMO) is a 
well-characterized member of ubiquitin-like protein that is involved in 
modification of many transcription factors and co-regulators, which leads to 
changes in their transcriptional activities and functions. In this work, we have 
investigated the role of sumoylation in modulating the transcriptional activities 
and biological functions of Stra13 and Sharp-1. We demonstrate that both 
Stra13 and Sharp-1 can be SUMO modified at evolutionarily conserved 
residues. SUMO modification does not alter the sub-cellular localization of 
either protein, however, it is required for both Stra13 and Sharp-1 to act as 
transcriptional repressors. Mutations of sumoylation sites, or co-expression of 
the SUMO protease SENP1 with Stra13 impairs its ability to repress cyclin D1 
and to mediate cell growth arrest and senescence. SUMO-dependent cell 
growth arrest mediated by Stra13 was associated with the recruitment of the 
co-repressor histone deacetylase 1 (HDAC1), as loss of SUMO sites in Stra13 
reduced interaction with HDAC1. On the other hand, sumoylation is important 
for Sharp-1 to repress MyoD transcriptional activity and skeletal muscle 
differentiation. These findings reveal new insights into the key role of SUMO 
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modification in regulation of the transcriptional activity and biological 
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1.1  The Basic Helix-Loop-Helix (bHLH) Protein family 
1.1.1 Features and classification of bHLH proteins 
Basic Helix-Loop-Helix (bHLH) proteins are a large super family of proteins 
involved in cellular differentiation, cell cycle arrest and apoptosis and so on. 
A highly conserved HLH region can be found in all of the bHLH proteins. 
This region comprises of two α-helixes. Each is 15-20 residues long and is 
separated by a variable loop region. Adjacent to the HLH region, they possess 
a highly basic DNA-binding region at their N- terminal. Since the first bHLH 
motif was identified in the mouse transcription factors E12 and E47 (Murre et 
al., 1989), a number of bHLH proteins have been identified in human, 
animals, plants, and fungi so far. Based on phylogenetic analyses, a 
subdivision of six monophyletic groups named A to F has been defined 
(Atchley and Fitch 1997; Simionato et al., 2007). The bHLH proteins in 
Group A and B typically bind to a consensus hexanucleotide E-box 
(CANNTG), where CACCTG or CAGCTG is for group A and CACGTG or 
CATGTTG is for group B. Group C bHLH proteins usually refer to bHLH-
PAS proteins because of a PAS domain following the bHLH motif (Murre et 
al., 1989; Crews, 1998). These bHLH-PAS proteins bind to the core 
sequences of ACGTG or GCGTG. Group D refers to those bHLH proteins 
without a basic domain and they are unable to bind DNA. In contrast to other 
bHLH proteins, they unusually function as antagonists of group A bHLH 
proteins (Benezra et al., 1990). Group E proteins are mainly including the 
bHLH-Orange family which shares another conversed domain named 
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‘Orange’ at the carboxyl-terminal part. The main character of Group F bHLH 
proteins is the presence of COE domain, an additional domain, which is 
involved both in dimerization and in DNA binding (Ledent and Vervoort, 
2001).  
1.1.2 The bHLH-Orange transcription factors 
The bHLH-Orange transcription factors are a large and diverse class of bHLH 
proteins and implicated in multiple signaling pathways (Sun and Taneja, 
2000; Yamada and Miyamoto, 2005; Sun et al., 2007). In addition to the 
bHLH domain, all these proteins contain a unique and highly conserved 
Orange domain. This Orange domain is a motif of ~35 amino acids, and also 
termed Helix III/IV. It is located at the C-terminal of the bHLH-O factors and 
is present for an additional protein-protein interaction interface and 
transcriptional regulation (Dawson et al., 1995). Based on the structure and 
phylogenetic analysis, the mammalian bHLH-O factors are classified into 
four subfamilies: Hes family including Hes1-7, Hey family including Hey1-2, 
Helt family and Stra13/Dec family which includes Stra13/Dec1 and Sharp-






 1.2   Stra13 
Stra13 (Stimulated with retinoic acid 13) belongs to the Stra13/DEC 
subfamily of bHLH-O factors. It is also known as Split and hairy related 
protein2 (SHARP2) in rat (Rossner et al., 1997), differentiated embryo-
chondrocyte expressed gene 1(DEC1) or bHLHB2 in chondrocytes (Shen et 
al., 1997; Sun et al., 2007), E47 interacting protein 1 (Eip1) (Dear et al., 
1997) and Cytokine response gene 8 (CR-8) in human (Beadling et al., 2001). 
The mouse Stra13 gene maps to chromosome 6E-F1, and the human 
homologue DEC1 gene maps to chromosome 3p26 (Antonevich and Taneja, 
1999). It encodes a 411 amino-acid transcriptional repressor which is widely 
Figure.1.1.1 The domain structure of bHLH-O factors   
 (Taken from Translational Oncogenomics 2007; 2:107-120) 
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expressed in numerous tissues and cell types. The gene was first cloned as a 
retinoic acid (RA)-inducible gene during the neuronal differentiation of P19 
mouse embryonic carcinoma cells (Boudjelal et al., 1997). The amino acid 
sequence of Stra13 shows the highest homology in the bHLH domain with 
mouse Hes1 proteins and Drosophila Hairy (H), Enhancer of Split (E (Spl). 
Similar to other bHLH-O factors, Stra13 proteins contain a bHLH motif in 
the N-terminal region, a proline-rich domain in the C-terminal and an Orange 
domain between bHLH and proline-rich domains. Unlike many other bHLH 
proteins that usually bind E-box (CANNTG) or N-box (CACNAG) which is 
a binding site for most bHLH factors, Stra13 binds to the class B site 
(CACGTG) and mediates transcriptional repression. Different from Hes/Hey 
proteins which usually repress gene transcription by recruiting the co-
repressor Groucho through the WRPW or YRPW motif, Stra13 mediates 
transcriptional activity by recruiting co-factors other than Groucho. High 
expression of Stra13 are found in normal muscle, heart, and liver, while its 
expression level is rather low in normal pancreas, kidney. High expression of 
Stra13 has also been shown in a variety of cancer cell lines including 
leukaemia, colon carcinoma, breast, gliomas and renal cancer (Li et al., 2002; 
Giatromanolaki et al., 2002; Ivanova et al., 2005). In addition, its expression 
is stimulated and up-regulated in response to various stimuli including serum 
deprivation, treatment of some reagents like TGFβ, retinoic acid, trichostatin 
A (TSA) and genotoxic agents. Numerous studies have shown its 
involvement in various processes such as cellular senescence, cell growth 
suppression, apoptosis, tissue regeneration, circadian rhythms, immune 
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responses, and oncogenesis (Boudjelal et al., 1997; Sun and Taneja, 2000; 
Sun et al., 2001; Beadling et al., 2001; Li et al., 2002; Shen et al., 2002). 
 
 1.3   The biological functions of Stra13 
 1.3.1 Transcriptional regulation 
Stra13 is a bHLH transcriptional repressor and usually exhibits a strong   
transcriptional repression activity which is regulated through the α-helices or 
DNA binding (Boudjela et al., 1997). Stra13 has been shown to repress 
Clock/Bmal 1-induced activation through direct DNA-binding, as its DNA-
binding mutants showed no repressive activity (Li et al., 2004). In addition, 
Stra13 represses transcription through interaction with co-repressors. Earlier 
studies in our lab suggest that Stra13 represses transcriptional activity at the 
promoter of both itself and c-Myc which is a cell proliferation-associated 
gene. Interestingly, further studies suggest that Stra13 represses the 
transcriptional activity of target genes through HDAC-dependent and HDAC-
independent pathways. The addition of trichostatin A (TSA), a specific histone 
deacetylase (HDAC) inhibitor, can relieve the repression in the transcriptional 
activity of Stra13 on its own promoter but not on the c-Myc promoter. In 
contrast, the repression of c-Myc expression is dependent on the interaction of 
Stra13 with the basal transcription factor TFIIB (Sun and Taneja, 2000). More 
and more work has been done to describe the repression activity of Stra13. Li 
and co-workers demonstrated that Stra13 repressed the expression of DEC2 
through direct DNA binding to the E-box in the proximal promoter of DEC2 
(Li et al., 2003). Stra13 was found to be strongly expressed in skeletal muscle 
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and represses MyoD (myogenic differentiation factor D)-mediated 
transactivation of PGC-1α (peroxisome-proliferator-activated receptor γ co-
activator-1α) and PRC (PGC-1 related co-activator) promoters (Hsiao et al., 
2009). However, in certain circumstances, Stra13 was also able to function as 
an activator of transcription. It has been shown that the cytokine-induced 
Stra13 expression has the ability to activate the transcription of STAT-
dependent cis-elements and increase the activity of pro-apoptotic Fas promoter 
(Ivanova et al., 2004). 
 1.3.2  Role of Stra13 in cell proliferation, differentiation and growth 
suppression 
Like most of the bHLH transcription factors, Stra13 is shown to be involved in 
regulating differentiation or proliferation of numerous types of cells, and 
therefore affects the growth of cells (Shen et al., 1997; Sun and Taneja, 2000). 
Growing evidence suggests that cells over-expressing Stra13 exhibit a 
diminished cell proliferation and growth. In a previous study, NIH3T3 cells 
transfected with Stra13 revealed a strong repression in the expression of the 
cell proliferation-associated gene c-Myc and reduction in colony-forming 
numbers compared with cells transfected with an empty vector (Sun and 
Taneja, 2000). The decrease in proliferation due to over-expression of Stra13 
is proportionally associated with the levels of Stra13 protein (Li et al., 2002). 
This inverse association of Stra13 with proliferation was further confirmed by 
recent study: Stra13 over-expression delayed wound healing and reduced cell 
proliferation, migration, and invasion rate assessed through MTS assay, in 
vitro wound healing assay, and in vitro invasion assay. This study further 
identifies that the inhibition of proliferation by Stra13 is associated with the 
8 
 
down-regulation of cyclin D1 leading to cell cycle arrest at G1 phase (Bhawal 
et al., 2011).  
Several studies have identified a critical role for Stra13 in cell differentiation. 
Overexpression of Stra13 in P19 cells promotes differentiation of neurons and 
represses differentiation of mesodermal/endodermal (Boudjelal et al., 1997). 
During the differentiation of human embyo chondrocytes, the level of Stra13 
is up-regulated; and this forced expression of Stra13 promotes chondrocyte 
differentiation (Shen et al., 2002). Stra13 was also shown to induce 
trophoblast stem cells into trophoblast giant cells (Hughes et al., 2004)), while 
it inhibits preadipocytes cells differentiation into adipocytes through 
regulating the expression of PPARγ (peroxisome proliferator-activated 
receptor) which is an adipogenic master gene (Shang and Waters, 2003). 
Taken together, these data strongly suggest that Stra13 is an important 
regulator in cell proliferation, differentiation and growth. 
1.3.3   Stra13 and apoptosis regulation 
Apoptosis plays a crucial role not only in eliminating old cells, unnecessary 
cells, and unhealthy cells to develop and maintain the health of the body, but 
also in preventing cancer development by limiting aberrant proliferation of 
damaged cells (Lowe et al., 2004). Recently, research has highlighted an 
important role for Stra13 in the regulation of apoptosis. Initial studies show 
that Stra13 is involved in apoptosis as evidenced by the activation effect of 
Stra13 on the pro-apoptotic Fas gene (Ivanova et al., 2004; Ivanov et al., 
2007). Our previous studies also demonstrate that Stra13 plays a crucial role in 
regulation of apoptosis (Sun et al., 2001; Thin et al., 2007). Stra13-/- mice 
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exhibit impaired apoptosis of thymocytes corresponding with the increased 
expression of pro-survival genes such as Bcl2 and the decreased expression of 
pro-apoptotic markers. Stra13 mediates apoptosis through regulating the 
expression of p53 which is a master regulator of apoptosis and p53-mediated 
apoptosis is essential for tumor development (Fridman and Lowe, 2003; Lowe 
et al., 2004; Thin et al., 2007). As such, Stra13-deficient thymocytes exhibit 
reduced γ radiation-induced apoptosis, along with decreased expression of p53 
and its key transcriptional targets Puma and Noxa (Thin et al., 2007). 
1.3.4   Stra13 in senescence induction 
Cellular senescence was first demonstrated as a process that limits the 
replicated life span of primary mammalian cells in culture. It is an irreversible 
growth-arrested and this state is achieved by cells in culture after a finite 
number of cell divisions (Hayflick and Moorhead, 1961). Senescent cells are 
characterized by a specific phenotype that includes enlarged cell size, flattened 
cell morphology which contains more granules, inability to synthesize DNA 
and irreversible growth arrest, senescence-associated β-galactosidase activity 
(SA-β-gal) and up-regulation of proteins involved in cell-cycle arrest such as 
p16 and p21(Dimri and Campisi, 1994; Dimri et al., 1995). The cellular 
mechanism of senescence is mainly related to the gradual shortening of 
telomeres due to the lack of expression of telomerase, the enzyme responsible 
for maintenance of telomeric ends (Shay and Wright, 2001; Stewart and 
Weinberg, 2000). Senescence can be initiated by different types of stress such 
as chromatin remodeling, DNA damage, oxidative stress, activation of 
oncogenes and chemotherapeutic agents (Serrano and Blasco, 2001). A 
number of studies have shown that cellular senescence usually utilizes the 
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p21/p53 and p16/pRB pathways (Campisi and Fagagna, 2007; Okada and 
Mak, 2004). Several genes related to the regulation of senescence have been 
identified to be part of either of p53 and pRB pathways (Ben-Porath, 2004; 
Hickman et al., 2002). 
Cellular senescence represents a potent antitumor mechanism (Campisi, 2005; 
Serrano and Blasco, 2001) and serves as an important barrier to tumor 
development in vivo. It is critical for precancerous cells to become tumor cells 
if they are bypassing senescence (Mooi and Peeper, 2006; Prieur and Peeper, 
2008). Various proteins are identified to regulate cellular senescence. Recent 
studies demonstrated that Stra13 is involved in cellular senescence. Over 
expression of Stra13 is able to promote or induce cellular senescence and 
arrest cell growth in p53-dependent manner in some cancer cell lines, and 
knockdown of DEC1 attenuates DNA damage-induced premature senescence. 
These data indicate that Stra13 may be a potential target for therapy of cancers 
(Qian et al., 2008; Xu et al., 2012). 
1.3.5  Role of Stra13 in the immune system 
The activation and development of T and B cells play a critical role in the 
immune response to antigens (Mondino et al., 1996). Several studies have 
indicated the role of Stra13 in the immune system by regulating B and T cells. 
Stra13 expression is strongly repressed during mouse B cell activation and 
negatively regulates B and T cell development (Seimiya et al., 2002 & 2004). 
Early evidence in our lab suggests that Stra13 is essential for cytokine 
production and clonal expansion in the process of T cell activation. Stra13 
deficiency can cause ineffective elimination of activated T and B cells which 
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leads to lymphoid organ hyperplasia due to the progressive accumulation, 
therefore resulting in the development of autoimmune disease  in  aging 
Stra13-/- mice consequently (Sun et al., 2001). These indicate that Stra13 is a 
key regulator of self-tolerance and for constraining of autoimmunity and 
therefore plays important roles in immune systems. 
1.3.6   Stra13 and Oncogenesis  
A growing body of evidence indicates that over-expression of Stra13 leads to 
some important tumor suppression including cell cycle arrest and growth 
suppression, cellular senescence (Sun and Taneja, 2000; Beadling et al., 2001; 
Seimiya et al., 2002; Qian et al., 2008). Stra13 expression has been shown to 
be down-regulated in some tumor cell lines. Intriguingly, however, its 
expression is up-regulated in many cancers such as human breast carcinomas, 
lung cancer and pancreatic cancer (Sun et al., 2007; Giatromanolaki et al., 
2003; Turley et al., 2004; Ivanova et al., 2005). Stra13 expression can be 
induced by hypoxia in many cancer cell lines including lung carcinoma A549, 
bladder cancer EJ-28, breast cancer HBL-100, kidney carcinoma 
RCC4(Wykoff et al., 2000; Ivanova et al., 2005). The expression of Stra13 is 
up-regulated in the absence of the von Hippel-Lindau tumor suppressor 
proteins (Ivanova et al., 2005). Li and coworkers reported that abundant 
expression of Stra13 can cause inhibition of proliferation, antagonize 
apoptosis induced by serum deprivation, moreover, it electively inhibits the 
activation of pro-caspases 3, 7, 8, 9 in colon carcinoma (Li et al., 2002). These 
findings suggest that Stra13 is expressed abundantly in a variety of tumors and 
has significant effects on carcinogenesis and tumor development. 
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1.3.7   Other functions of Stra13  
In addition to the functions mentioned above, Stra13 is also involved in many 
other biological functions. Overexpression of Stra13 in mouse embryonal 
carcinoma-derived clonal cell line ATDC5 cells promotes chondrocyte 
differentiation (Shen et al., 2002). Stra13 also plays critical role in muscle 
differentiation and regeneration. Stra13-deficient mice exhibit impaired 
regeneration in response to injury characterized by muscle necrosis and 
fibrosis. Double mutants lacking both Stra13 and dystrophin exhibit reduced 
myofiber integrity and an earlier onset of muscle degeneration compared to 
dystrophin-deficient mutants (Sun et al., 2007; Vercherat et al., 2009). Stra13 
is expressed in mouse peripheral organs and significantly implicated in the 
regulation of circadian rhythms which mediate physiology and behavior of 
most organisms by mediating a subset of circadian physiological outputs in 
peripheral organs (Grechez-Cassiau et al., 2004). ROS (radical oxygen 
species) production has been implicated in the mediation of some diseases 
such as diabetes mellitus, ischemia, glomerulonephritis and cancers. Over 
expression of Stra13 in mouse podocytes can regulate the cellular redox state 
of podocytes and therefore protects cells from ROS-induced damage (Bek et 
al., 2003). 
1.4  Sharp-1 
Mus musculus Sharp-1 (Enhancer-of-Split and Hairy-related protein 1), also 
known in homo sapiens as DEC2 (differentiated embryo chondrocyte protein 
2), BHLHE41 or bHLHB3, is a 410 amino acid transcription factor. It is the 
other member of the Stra13/DEC subfamily of bHLH-O factors. It was 
originally identified in rat brain and subsequently in human and mouse as well 
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(Azmi et al., 2003; Rossner et al., 1997). Sharp-1 shares very high homology 
(96%) with Stra13 within the bHLH domain (Azmi et al., 2003), whereas, the 
amino acid sequences of the Orange domain are only moderately conserved, 
with a homology of 52%. Similar to Stra13, Sharp-1 usually functions as a 
transcriptional repressor, but lacks a WRPW motif in the C terminus for 
recruitment of the Groucho co-repressor. Moreover, Sharp-1 is also found to 
bind to the E box motif (CANNTG). A growing body of studies have 
identified that Sharp-1 is involved in the regulation of cell cycle, apoptosis, 
gene expression proliferation and differentiation of several cell types including 
epithelial cells, myoblasts and fibroblasts (Sato et al., 2008, Liu et al., 2009; 
Cho et al., 2009; Garriga-Canut et al., 2001; Gulbagci et al., 2008, Azmi et 
al., 2004).  
 
1.5   The biological functions of Sharp-1 
1.5.1 Regulation of gene expression by Sharp-1 
Given the high homology (96%) between Stra13 and Sharp-1 in the basic 
region of the bHLH domain, which is DNA-binding domain, Sharp-1 regulates 
the expression of some similar downstream target genes. Moreover, both 
Stra13 and Sharp-1 cross-regulate each other. Stra13 has been identified to be 
a target for repression mediated by Sharp-1, and the activity of Sharp-1 was 
shown to be significantly repressed by over-expression of Stra13 (Azmi and 
Taneja, 2002; Azmi et al., 2003; Li et al., 2003). Sharp-1 is able to repress 
transcription of both TATA-containing and TATA-less promoters when 
recruited via a Gal4 DNA binding domain (DBD), and over-expression of 
Sharp-1 represses transcription of a reporter construct containing the M1 
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promoter. Further study suggests that this repression occurs when Sharp-1 is 
bound either proximally or more distally to the promoter (Garriga-Canut et al., 
2001). A previous study in the lab identified that Sharp-1 regulates 
myogenesis by inhibiting the activity of myogenic bHLH factors such as 
MyoD (Azmi et al., 2004). It was reported that Sharp-1 can negatively 
regulate the expression of VEGF (vascular endothelial growth factor) which is 
involved in the pathological conditions (Sato et al., 2008).  
1.5.2 Sharp-1 and Cell differentiation 
Sharp-1 is highly expressed in proliferating C2C12 myoblast cells and is 
down-regulated during myogenic differentiation (Azmi et al., 2004). Over-
expression of Sharp-1 in C2C12 cells results in inhibition of muscle 
differentiation by negatively regulating the activity of MyoD, a master gene of 
muscle lineage (Azmi et al., 2004). Consistently, expression of Sharp-1 was 
found to be up-regulated in inclusion body myositis when mesangioblasts fail 
to differentiate into skeletal muscle (Morosetti et al., 2006). In addition, the 
expression level of Sharp-1 was found to be modulated during adipogenesis 
and the adipogenic differentiation was inhibited by Sharp-1 through regulation 
of C/EBP activity. Sharp-1 mRNA levels were transiently down-regulated 
during differentiation in 3T3L1 and 10T1/2 cells, and up-regulated again 
during terminal differentiation. Protein interaction studies reveal that Sharp-1 
represses the transcriptional activity of both C/EBPβ and C/EBPα through 
interacting with both of them and enhances the association between histone 




1.5.3 The regulatory effects of Sharp-1 during myogenesis 
1.5.3.1   Myogenesis and its regulation  
Myogenesis, or the development of skeletal muscle, occurs during embryonic 
development. It mainly involves three stages: 1) proliferation of myoblasts 
(muscle precursor cells derived from somites) in the early development of an 
embryo; 2) fusion of myoblasts; 3) differentiation and alignment of the 
myoblasts into the myotubes (multi-nucleated fibers). Myogenesis also occurs 
in the adult skeletal muscle in response to damage or injury. Myogenesis is a 
complex and tightly regulated process. Typically, this process is regulated by 
two groups of transcription factors: the bHLH myogenic regulatory factors 
(MRFs) and myocyte enhancer factor 2 (MEF2) factors. They act together to 
drive and regulate the terminal differentiation of myoblasts into myotubes by 
activating skeletal muscle specific promoters (Sabourin and Rudnicki, 2000).  
MRFs are the master regulators governing myogenesis. Any deficiency or 
abnormality in MRF can lead to defects in skeletal muscle differentiation and 
development. MRFs include MyoD (Myogenic differentiation factor D), Myf5 
(myogenic factor 5), Myog (myogenin) and Myf6 (myogenic factor 6, also 
known as MRF4). MyoD and Myf5 are believed to be required for myogenic 
determination, determining the differentiation potential of an activated 
myoblast, whereas myogenin and MRF4 play a role in terminal differentiation. 
So the process of myogensis is started by the primary MRFs, MyoD and Myf-
5 which are required to convert the proliferating somitic cells to the myogenic 
lineage. Subsequently, the proliferating myoblasts can further differentiate into 
myocytes and mature into myofibers under the action of the secondary MRFs, 
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myogenin and MRF4. A conserved basic DNA-binding domain which is 
essential for sequence-specific DNA binding is usually localized in the MRF 
proteins; in addition, the MRF proteins contain a helix-loop-helix motif 
required for heterodimerization with ubiquitously expressed E proteins 
(Weintraub et al., 1991; Olson and Klein, 1994). MRFs bind to E-box 
sequences (CANNTG) in target gene promoters to turn on their expression 
during skeletal muscle differentiation. They do not act alone, but exist as part 
of complex signaling cascades that control every stage of myogenesis (Le 
Grand and Rudnicki, 2007).  
Among MRFs, MyoD is expressed in proliferation myoblasts. Once activated, 
MyoD is involved in the regulation of early and late differentiation markers 
such as myogenin, myosin heavy chain (MHC), muscle creatine kinase and 
Troponin T (Penn et al., 2004). So it plays a central role in the regulation of 
entire skeletal muscle differentiation. Due to its importance in the process of 
myogenesis, modification on MyoD activity is tightly controlled. MyoD is 
directly acetylated by cofactor p300/CBP-associated factor (PCAF) at its three 
conserved lysine residues K99, K102 and K104, which leads to the activation 
of MyoD and induction of expression of target genes during myogenesis, as 
mutation of these three lysines impair the activity of MyoD in muscle 
differentiation (Sartorelli et al., 1999; Bharathy and Taneja, 2012). On the 
other hand, some co-repressors can be recruited to MyoD to negative regulate 
its activity. One well-studied example is the proteins in HDAC family such as 
HDAC1 and SirT1. HDAC1 can be recruited to muscle promoters through 
their association with MyoD and cause deacetylation of histone and therefore 
inhibit muscle differentiation (McKinsey et al., 2001). SirT1 block MyoD 
17 
 
activity through forming a complex with MyoD and PCAF (Fulco et al., 
2003). Recent studies in our lab provide evidence that methylation of MyoD 
by lysine methyltransferase G9a regulates skeletal muscle differentiation. G9a 
interacts MyoD and methylates MyoD at Lysine 104, which leads to the 
inhibition of MyoD activity (Ling et al., 2012a). 
1.5.3.2   The modulation of Sharp-1 during myogenesis 
Skeletal muscle differentiation is mainly controlled by the transcriptional 
activity of MRFs together with epigenetic modifications. Therefore, the 
modulation of myogenesis is usually through the regulation of MRFs activity 
by its association with co-factors including activators and inhibitors. One 
inhibitor of myogenesis is Sharp-1 which was demonstrated in our previous 
study to inhibit skeletal muscle differentiation through suppression on the 
activities of myogenic transcription factors. Expression of Sharp-1 declines 
during myogenic differentiation and its over-expression impairs myogenesis 
through antagonism of MyoD, this strongly suggests that Sharp-1 is able to 
inhibit myoblast differentiation into myotubes. Moreover, Sharp-1 was found 
to inhibit the MyoD-dependent myogenic conversion of mouse fibroblast cell 
line C3H10T1/2 into myotubes upon ectopic expression of MyoD, with 
corresponding repression of myogenin, MEF2C and myosin heavy chain 
(Azmi et al., 2004; Ling et al., 2012b). One of the mechanisms involved in 
this inhibitory effect of Sharp-1 is through its inhibition of the transcriptional 
activity of E protein-MyoD complexes: Sharp-1 dimerizes with MyoD and E-
proteins through its HLH domain and prevents the formation of the functional 
MyoD/E protein dimers which is essential to turn on the differentiation 
program and hence blocks myogenic differentiation (Azmi et al., 2004; 
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Fujimoto et al., 2007). The dimerization of MyoD and E protein with Sharp-1 
can only partially block MyoD DNA-binding, as a tethered MyoD-E47 dimer 
is unable to completely overcome Sharp-1-mediated repression. Therefore, 
other mechanisms are also involved in this regulation. It was reported that 
Sharp-1 represses transcription of promoters which contain both TATA and 
TATAless in a HDAC-dependent manner in neurons (Garriga-Caut et al., 
2001). Interestingly, HDAC1 is not involved in Sharp-1-mediated repression 
of MyoD activity in muscle cells (Fujimoto et al., 2007). Our recent study has 
indicated that the transcriptional co-factor G9a, is involved in Sharp-1 
mediated inhibition of muscle differentiation. Sharp-1 directly recruits G9a 
onto the MyoD target promoters and enhances the transcriptional repression of 
MyoD during the muscle differentiation. Consistent with a differentiation 
block, the association between Sharp-1 and G9a results in increased repressive 
histone H3 lysine 9 di-methylation (H3K9me2) chromatin marks as well as 
MyoD methylation at lysine 104 (K104). This was further confirmed by knock 
down study. RNAi-mediated reduction of G9a, or inhibition of its activity in 
Sharp-1 overexpressing cells restores differentiation concomitant with 
removal of repressive methylation marks (Ling et al., 2012b). 
1.5.4 Other functions of Sharp-1 
Sharp-1 is expressed widely in a number of cell types and therefore involved 
in many other physiological functions such as sleep length, circadian rhythms, 
tumor suppression and in Th2 lineage commitment (Honma et al., 2002; Azmi 
et al., 2004; Rossner et al., 2008; Gulbagci et al., 2009; Yang et al., 2009a; He 
et al., 2009). Similar to Stra13, through direct associations with Bmal1 and/or 
competition for E-box elements, Sharp-1 is also able to regulate the 
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mammalian molecular clock and functions by repressing Clock/Bmal1-
induced transactivation of the mouse Per1 promoter (Honma et al., 2002). 
Sharp-1 is a regulator of sleep length as a mutation in Sharp-1 is associated 
with human short sleep phenotype. The Sharp-1 deficiency mice displayed 
less sleep time and increased vigilance time (He et al., 2009). In addition, 
Sharp-1 is found to be expressed in several tumor cell types and plays 
important roles in regulating tumor development. For example, Sharp-1 was 
identified to be a crucial regulator of breast cancer. It not only displays strong 
anti-apoptotic effects on apoptosis in breast cancer MCF-7 cells, but also can 
repress breast cancer metastasis by degrading HIF (hypoxia-inducible factors) 
(Wu et al., 2011; Montagner et al., 2012). Sharp-1 is involved in the 
regulation of apoptosis by inhibiting the expression of pro-apoptotic factor 
Bim (Bcl-2-interacting mediator of cell death) in human oral cancer HSC-3 
cells (Wu et al., 2012). 
 
Generally speaking, many of the functions of these two transcription factors 
Stra13 and Sharp-1 seem well-characterized. However, the molecular 
mechanisms through which these diverse biological functions are regulated are 
poorly understood. Potentially, they may occur by association with distinct co-
regulators in different cell types, or by altering sub-cellular localization. 
Alternatively, post-translational modifications such as sumoylation may create 





1.6   Sumoylation  
Post-translational modifications are known to alter many diverse biological 
functions of proteins and participate in most cellular activities (Hershko and 
Ciechanover, 1998; Pickart, 2001). One of modifications is sumoylation which 
is characterized by covalent and reversible binding of SUMO (Small 
Ubiquitin-related Modifier) to a target protein. SUMO is a well-characterized 
member of a growing family of ubiquitin-like proteins implicated in 
posttranslational modifications, which takes place at all stages of development 
in multicellular organisms (Erica, 2004). SUMO protein is usually covalently 
attached to an obligatory lysine in canonical ψKXE SUMO motifs (whereψ is 
a hydrophobic amino acid, K is the acceptor lysine for covalent attachment of 
SUMO, and X is any residue, and E is glutamic acid) in the substrate. So far, 
four isoforms of SUMO termed SUMO-1,-2,-3 and -4 are identified (Tatham 
et al., 2001). Most of the identified SUMO-modified proteins are conjugated 
to SUMO-1. SUMO-2 and SUMO-3 share 45% identity to SUMO-1, but they 
are 96% identical with each other, and they are usually referred to as SUMO-
2/3. Most of SUMO-1 is conjugated to its target substrates in mammalian 
cells, whereas SUMO-2 and SUMO-3 usually exist freely in the cells, and 
their conjugation happens upon stress (Saitoh and Hinchey, 2000). SUMO-4 
was found recently in spleen cells, kidney, but it is still unclear whether it can 
be targeted to any cellular protein (Gareau and Lima, 2010). These proteins 
are ~12 kDa in size and have a similar three-dimensional structure as ubiquitin 




1.6.1 Sumoylation pathway 
The biochemistry process of sumoylation is similar to ubiquitination, 
involving a three-step reaction which includes activation, transfer, and ligation 
of SUMO. Specifically, as shown in Figure 1.6.1, SUMO is activated by an 
E1-activating enzyme, which is a SAE1/SAE2 heterodimer in human or 
Aos1/Uba2 in yeast in an ATP-dependent manner. Activated SUMO is 
transferred to the sole E2-conjugating enzyme Ubc9, and subsequently is 
attached to a specific lysine residue in the substrate proteins with the aid of 
E3-SUMO ligases which are not essential but usually able to enhance the 
sumoylation level of substrate proteins. Some E3 ligases have been identified 
such as PIAS (Protein Inhibitor of Activated Stats) family, Polycomb, and 
RanBP. Among them, PIAS proteins (PIAS1, PIAS3, PIASxa and PIASy) are 
the most known and extensively studied SUMO ligases (Melchior, 2000; 
Kotaja et al., 2002). Sumoylation is a highly dynamic and reversible process, 
whereby SUMO conjugation of proteins is readily reversed by Sentrin/SUMO-
specific proteases or cellular isopeptidases (Ulps in yeast and SENPs or 
SUSPs in human), which can cleave or remove SUMO from its target 












1.6.2 Functions of sumolylation 
Sumoylation plays very critical roles in regulating protein functions involved 
in a wide range of cellular processes. Firstly, sumoylation pathway itself is a 
key regulator of many cellular activities. Its importance has been confirmed 
through some knockout and knockdown studies. When Ubc9 which is the sole 
E2-conjugating enzyme essential for SUMO conjugation is removed in the 
chicken DT40 lymphocyte cells, chromosome segregation and nuclear 
Figure 1.6.1 The SUMO conjugating pathway. SUMO is 
synthesized as a precursor and processed by hydrolases to make the 
carboxy-terminal double-glycine motif available for conjugation 
(vertical arrow). It is subsequently conjugated to proteins by means 
of E1 activating (SAE1/SAE2), E2 conjugating (Ubc9) and E3 
ligating enzymes (PIAS family or RanBP2, not shown). The E3-
like proteins might serve to increase the affinity between Ubc9 
(E2) and the substrates by bringing them into close proximity in 
catalytically favourable orientations, allowing sumoylation to occur 
at a maximal rate. The resulting isopeptide bond is stable and its 
disruption requires a desumoyulating enzyme (Taken from EMBO 
reports 2003; 4:137-143). 
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organization become defective, leading to cell death by apoptosis eventually 
(Hayashi et al., 2002). More and more evidence suggests the essential role of 
SUMO system in early mammalian development. Nacerddine et al provided 
evidence that Ubc9 is critical for early embryonic viability and defects may 
cause the lethality (Nacerddine et al., 2005). Knockout of SUMO1 in mice 
leads to lethality of embryos, and haploinsufficiency of SUMO1 causes a 
defect in (split lip and palate) in mice and possibly in human development 
(Alkuraya et al., 2006).  On the other hand, SUMO can be conjugated to other 
proteins, and SUMO targets are very versatile and fall into various categories 
such as signal transducers, viral proteins, enzymes and transcription factors. 
Due to the diverse targets, the functional consequences of SUMO modification 
are also multiple. Sumoylation can modify a large number of proteins in many 
different pathways. But unlike ubiquitination which usually facilitates the 
target proteins for degradation, sumoylation has diverse functional 
consequences including regulation of protein-protein interaction, changes in 
subcellular localization (Seeler and Dejean, 2001; Gill, 2003), protein 
stability, genome integrity, chromatin structure regulation (Matunis et al., 
1998), DNA-binding (Goodson et al., 2001) and alteration of transcriptional 





1.6.2.1   Regulation of transcriptional activity by SUMO modification 
Transcription factors, co-regulators including co-activators and co-repressors 
are the main targets of sumoylation. Sumoylation can alter their activities and 
lead to changes in their functions and gene expression (Johnson, 2004; Gill, 
2004). A growing number of transcription factors and transcriptional co-
regulators including co-activators and co-repressors have been identified to be 
modified by SUMO conjugation. This attachment of SUMO is able to affect 
the stability, activity, DNA-binding and localization of specific transcription 
factors. Even though the effects are various, in most cases, sumoylation leads 
to transcriptional repression, as shown in Table 1, the transcriptional activities 
of the majority of proteins is negatively regulated by sumoylation (David et 
Figure 1.6.2 Physiological functions of Sumoylation (Modified 
from EMBO Reports 2003; 4:137-143) 
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al., 2004). There are only a few proteins, such as heat-shock transcription 
factors HSF1 and HSF2, in which sumoylation appears to increase their 
transcriptional activities (Hietakangas et al., 2003; Hilgarth et al., 2009). 
 




One explanation for this transcriptional repression by SUMO modification is 
that the sumoylation sites of proteins are located within their previously 
characterized repression or negative regulatory domains, as both mutation of 
the SUMO-acceptor lysines and over-expression of SENP1, the de-
SUMOylation enzyme,  can  lead to an important enhancement  in the 
transcription activities of numerous transcription factors such as the 
Table 1: Taken from Seminars in Cell & Developmental Biology 
2004; 15:201-210 
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CAAT/Enhancer-binding (C/EBP) proteins, Sp3, Androgen receptor (AR) and 
Smad4 (Poukka et al., 2000;  Yang et al., 2003;  Ross et al., 2002; Gill, 2003). 
Another possibility is that SUMO attachment inhibits transcription activity by 
promoting the binding of a transcriptional co- repressor (Figure 1.6.2.1) (Gill, 
2005). SUMO conjugation of transcription factors alters interactions between 
protein and protein to facilite recruitment of co-repressors (CoR) and therefore 
results in inhibition of target gene expression. For example, sumoylation of 
p300 affects the interaction of HDAC6 with the CRD1 domain on p300, and 
this SUMO-dependent binding leads to the transcriptional repression of p300 
(Girdwood et al., 2003). Yang et al also observed that sumoylation of Elk-1 is 
responsible for the increased association between histone deacetylase HDAC2 







Figure 1.6.2.1  Effect of sumoylation on repression of transcription 




1.6.2.2    Regulation of nuclear or sub-cellular localization  
Most of SUMO target proteins are localized in nuclear bodies and a growing 
body of evidence implicates that SUMO modification alters the nuclear or 
subcellular localization of its target proteins. Sumoylation of RanGAP1 
promotes its relocation from the cytoplasm to the nuclear pore (Matunis et al., 
1998). The p53-related p73α protein has been shown to relocalize from the 
soluble to the insoluble nuclear fraction upon sumoylation (Muller et al., 
2000). The best-characterized protein that was related to the altered 
subcellular localization caused by SUMO modification is the tumor suppressor 
PML which is the central component in the PML nuclear bodies (NBs). 
Sumoylation of PML has been shown to be essential for formation of 
morphologically normal NBs and for recruitment of interacting proteins 
(Kamitani et al., 1998). Mutation of the SUMO acceptor lysines in PML or 
overexpression of a SUMO protease induces many of the interacting proteins 
such as Sp100, CBP, ISG20 to translocate from the PML NBs to the nucleus 
(Zhong et al., 2000a; Best et al., 2002). SUMO conjugation pathway has also 
been shown to play a role in nuclear trafficking in budding yeast (Stade et al., 
2002) and nuclear import in mammalian cells (Huang et al., 2003). By 
contrast, sumoylation is not required for the nuclear localization of some 
proteins such as HIC1 and EKLF (Stankovic-Valentin et al., 2007). 
1.6.2.3    Senescence modulation 
Sumoylation plays a critical role in the cellular senescence. One of the 
important indications for the role of sumoylation on senescence is that some 
proteins in SUMO conjugation pathway are implicated to be involved in 
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cellular senescence through the regulation of the two main senescence 
pathways: p21/p53 and p16/ pRB pathways (Campisi, 2005). One example is 
PIASy, a member of the largest families of SUMO-specific ligases. The 
expression level of PIASy is significantly increased during senescence. On the 
other hand, cellular senescence is induced when PIASy is over-expressed, and 
mutation of the PIASy E3 ligase active site can abolish this effect. Further 
studies suggest that role of PIASy influencing cellular senescence is through 
regulation of the pRB status (Bischof et al., 2006). Another example is that a 
number of SUMO proteases, SENP family are found to be involved in the 
regulation of senescence. Repression of SENP1 is able to induce p53-
dependent premature senescence (Yates et al., 2008). The second indication 
for the role of sumoylation on senescence is that a growing number of 
senescence-associated proteins have been demonstrated to go through SUMO 
conjugation. The most important examples are the major players in senescence 
p53 and pRB, which have been shown to be regulated by sumoylation. A 
series of data have shown that the transcriptional activity of p53 is positively 
regulated by SUMO modification. Therefore, the expression of its target gene 
p21, also a senescence-related protein, is increased. Similarly, the repression 
activity of pRB on E2F-regulated genes is also mediated by sumoylation 
(Bischof et al., 2006). 
1.6.2.4    Carcinogenesis 
As a growing number of oncogenes and tumor suppressor genes turned out to 
be SUMO targeted, studies are being focused on the effects of sumoylation in 
carcinogenesis and its future cancer therapies. The most studied example is 
that the tumor suppressor gene p53 which is the most important regulator in 
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human cancer (Brady and Attardi, 2010). In the past decade, several groups 
have demonstrated that sumoylation of p53 can increase its transcriptional 
activity which leads to induction of apoptosis (Wu and Chiang, 2009). Further 
studies by Lee et al showed that the SUMO-specific protease (SUSP) is able to 
regulate the stability of p53, therefore affects apoptosis and cell growth arrest 
(Lee et al., 2006). Sumoylation has been identified to impact the 
inflammation-induced cancer by modulating effect on NF-kB signaling. 
Sumoylation of IkBα leads to its stabilization, inhibition of ubiquitin-
dependent degradation and blocking of NF-kB-triggered transcriptional 
activation (Desterro et al., 1998). Since increasing evidence suggests that 
sumoylation plays a critical role in cancer-related processes, it is possible 
SUMO machinery will be an attractive upcoming target for potential 
therapeutics. 
1.6.2.5    Other SUMO-related biological functions 
Besides the above mentioned functions, there are some processes which 
involve the regulation of SUMO conjugation. Tanaka et al demonstrated that 
sumoylation plays an important role in altering structure of higher-order 
chromatin and segregation of chromosome by showing that S.pombe strains 
are sensitive to DNA damaging agents, and grow very poorly, and have 
aberrant mitosis and frequent chromosome loss although viable if they are 
lacking sumoylation (Tanake et al., 1999). In addition, evidence is 
accumulating to show that SUMO controls pathways which are important for 
the surveillance of genome integrity and stability (Muller et al., 2004), 
protein-protein interaction, inhibition of ubiquitin-mediated degradation (Gill, 
2005). SUOM pathway is identified to be involved in formation of myotube 
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formation, neural crest and muscle development (Riquelme et al., 2006; Luan 
et al., 2013). 
1.6.3 Molecular mechanisms of SUMO modification 
Even though there are various types of SUMO target proteins and the 
functional consequences of SUMO modification are diverse and difficult to 
predict, three possible mechanisms are reported to explain the consequences 
caused by SUMO modification on the molecular level, as shown in 
Figure.1.6.3. First, sumoylation can change protein surface and thereby 
interfere with the association between the target and its partner. Consequently, 
sumoylation is able to alter protein-protein interactions. For instance, only 
sumoylated p300 is able to bind the co-repressor HDAC6, and therefore 
results in transcriptional repression (Girdwood et al., 2003). In addition, 
sumoylation of E2-25k inhibits its interaction with ubiquitin E1 enzyme 
(Pichler et al., 2005). The second mechanism is that the covalently attached 
SUMO can provide a new binding site to the substrate to recruit other 
interacting partners in a sumoylation-dependent manner. For example, 
sumoylation of PML can recruit the ubiquitin ligase RNF4 and regulate its 
functions (Maroui et al., 2012). Lastly, sumoylation can induce either specific 
changes at critical interfaces of the substrate protein or general conformation 
changes, thereby altering its activity directly. One of the examples is that 
sumoylation leads to a conformational change in TDG (thymine DNA 
glycosylase), which reduces its binding with DNA and facilitates it to release 









1.6.4 Regulation of sumoylation 
SUMO conjugation is a dynamic and reversible process. A growing number of 
evidences implicate that sumoylation can be regulated at different levels. 
Firstly, sumoylation can be regulated at the level of attachment. For instance, 
E3 SUMO ligases which are usually able to enhance sumoylation of substrates 
can be mediated, and therefore regulates sumoylation. Lee et al reported that 
the DEAD-BOX protein DP103/Ddx20/Gemin-3 can enhance sumoylation of 
SF1 in a PIASy-dependent manner (Lee et al., 2005). It is well-known that 
sumoylation level can be increased upon various forms of cellular stress 
including oxidative, ethanol stimuli, oxygen/glucose deprivation and 
hypothermia in neurons (Saitoh and Hinchey, 2000; Bossis and Melchior, 
Figure 1.6.3 Molecular mechanisms of sumoylation. a) 
Sumoylation can interfere with the interaction between the target and 
its partner, in which case the interaction can only occur in the absence 
of sumoylation. b) Sumoylation can provide a binding site for an 
interacting partner. c) Sumoylation can result in a conformational 




2006; Agbor and Taylor, 2008). Sumoylation could also be regulated through 
removal of SUMO by SUMO proteases like SENPs. In some cases, 
sumoylation of proteins is regulated by association with other proteins. 
Sumoylation of p53 and Mdm2 in vivo is enhanced by interacting with ARF, 
the tumor suppressor. Similarly, sumoylation of MEF2 and HIC1 can be 
enhanced by binding to HDACs (Grégoire and Yang, 2005; Stankovic-
Valentin et al., 2007). In contrast, sumoylation of Sp3 is repressed when 
bound to DNA (Sapetschnig et al., 2002). Recently, more and more data 
suggested that sumoylation can be modulated through crosstalk with other 
post-translational modifications through targeting the same lysine.  
1.6.5   Relationship between sumoylation and other post-translational 
 modifications 
SUMO is conjugated to lysine residue of the substrate proteins, which is also 
the target of other post-translational modifications such as ubiquitination, 
acetylation, phosphorylation and methylation. So there is a complex interplay 







SUMO is referred to as the small ubiquitin-related modifier, so SUMO is 
highly related to ubiquitin. Even though SUMO-1 is only 18% identical to 
ubiquitin, they share a very similar protein fold. In addition, SUMO 
conjugation pathway also shares striking similarities to ubiquitination 
pathway. Firstly, both SUMO and ubiquitin covalently attach to target proteins 
via an iso-peptide bond between a C-terminal glycine in the Ubl and a lysine 
residue in the substrate. Secondly, some of the enzymes such as E1 activating 
and E2 conjugating enzymes involved in both of the pathways are quite 
related. In addition, both sumoylation and ubiquitination are dynamic and 
reversible (Pickart, 2001; Kim et al., 2002). However, even though they share 
great similarities, each has its own specific proteases to regulate the 
Figure 1.6.5 Complex interplay between sumoylation and other post-
translational modifications (Taken from Biochem J 2010; 428:133-145) 
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conjugation pathways (Kim et al., 2002). In spite of the similarities between 
these two modifications, the functional consequences of target proteins are 
quite different. Unlike ubiquitination whose central role is to induce 
degradation of target proteins, sumoylation has various functions on substrates 
as shown on Figure 1.8.2. Due to the common lysine residues they share in the 
same proteins, in some cases, they have been shown to compete or interfer 
with each other. For example, sumoylation of IkB blocks poly ubiquitination 
and subsequent proteasomal degradation which is ubiquitin-dependent 
(Desterro et al., 1998). Many proteins have been identified to be regulated by 
both sumoylation and ubiquitination, but with different consequences.  
Sumoylation is also associated with other post-translational modifications. 
Studies reveal that several proteins such as MEF2A (myoctye enhancer factor 
2A), Sp3, p300 and HIC1 hypermethylated in cancer) have been shown to be 
modified by both sumoylation and acetylation at the same lysine residue, and 
in all the cases, the two modifications act antagonistically via competition for 
the target lysine (Sapetschning et al., 2002; Bouras et al., 2005; Stankovic-
Valentin et al., 2007). On the other hand, sumoylation can directly regulate 
acetylation through modification of HDACs which in turn mediate 
sumoylation of proteins through their E3-like activity (Grégoire and Yang, 
2005). In addition, phosphorylation of c-jun and IkBα leads to reduced SUMO 
attachment (Desterro et al., 1998; Muller et al., 2000). Chemically-induced 
hyperphosphorylation of PML significantly decreases its sumoylation, 
indicating that the sumoylation of PML is phosphorylation-dependent (Muller 
et al., 1998). Similarly, the sumoylation of E1k1 is inhibited by its 
phosphorylation (Yang et al., 2003), whereas phosphorylation of HSF1 (heat-
35 
 
shock factor 1) requires its sumoylation (Hietakangas et al., 2003). Taken 
together, there is a cross-talk between sumoylation and other modifications. 
 
1.7    Co-factors regulating transcription factors 
As discussed above, post-translational modifications such as sumoylation play 
critical roles in mediating functions of transcription factors. On the other hand, 
some cofactors including co-activators or co-repressors are also significantly 
involved in the regulation of their functions. The mechanisms of these actions 
are usually link to the modification of the chromatin structure and thereby 
make the associated DNA more or less accessible to transcription. Many 
proteins have been identified to function as cofactors. Among these, HDAC 
(Histone deacetylase) and G9a (H3K9 methyltransferase) are two of the 
important co-repressors which are able to mediate transcriptional repression 
by modifying chromatin enzymes. 
1.7.1   HDAC family in mammals 
 HDACs belong to a family of chromatin-modifying enzymes. They control 
gene expression by catalyzing deacetylation of lysine residues of histones 
through removal of acetyl groups from histone tails. They also can modulate 
functions of non-histone proteins such as p53 (Luo et al., 2000), HSP90 (Bali 
et al., 2005), or α-tubulin (Hubbert et al., 2002). Extensive studies revealed 
that HDACs play a key role in the regulation of gene expression and activity 
of numerous proteins involved in various cellular processes like cell cycle 
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progression, cell growth, differentiation, apoptosis, cellular senescence and 
carcinogenesis.   
 HDAC family was first discovered in yeast. In mammals, 18 HDACs have 
been identified so far, which are devided into four classes based on their 
homologies to yeast (Ropero and Esteller, 2007). These enzymes play 
different roles and are not redundant in function or activity. Class I HDACs, 
including HDAC1, 2, 3 and 8, are the closest homologs of yeast Rpd3, which 
is the main HDAC regulating the global level of histone acetylation in yeast 
(Kurdistani et al., 2002). They are predominantly localized in the nucleus and 
are expressed in a wide range of human tissues and cell lines. Class II HDACs, 
which are sub-divided into class IIa (HDAC4, 7, and9) and IIb (HDAC6 and 
10), show its similarity to yeast protein HDA1. Their expression is tissue-
specific, and can traffic between the cytoplasm and nucleus, so they may 
acetylate some non-histone proteins. Some transcription factors such as MEF2 
have been identified to be repressed by this class HDAC to regulate tissue 
growth (McKinsey et al., 2000). Class III HDACs which are NAD+ -
dependent, comprises SIRT1-7 that are homologous to yeast SIR2 family. The 
localization and tissue distribution of proteins in this class is not clear yet. 
Class IV group has only one member HDAC11, which shares some features of 
both class I and II HDACs (Gregoretti et al.,  2004).  
 
1.7.2 HDAC1 
HDAC1 was the first protein to be shown to have histone deacetylase activity 
(Vidal and Gaber, 1991). Gene targeting studies demonstrated that HDAC1 is 
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a major deacetylase in mouse embryonic stem (ES) cells and essential for 
embryogenesis. Further study suggests that HDAC1-null embryonic stem cells 
exhibit a proliferation defect and mouse embryos with deleted HDAC1 die at 
E9.5 (embryonic day 905) (Lagger et al., 2002; Montgomery et al., 2007). 
Chromatin immunoprecipitations (ChIP) assays have shown that HDAC1 
binds to the regulatory region of a large number of genes, especially 
transcription factors such as Rb, Mad, nuclear hormone receptors and p53 
(Cress and Seto, 2000; Ng and Bird, 2000). HDAC1, like other HDACs, lacks 
a DNA binding domain, does not directly bind to DNA. Instead, it usually 
associates with a DNA binding protein to target specific chromatin regions by 
transcription and chromatin-related factors to form large multiunit protein 
complexes (Glozak et al., 2005). 
 
1.8    Physiological functions of HDAC1 
1.8.1   Transcriptional regulation  
It is well known that histone acetylation plays a critical role in the 
transcriptional regulation of many target genes through its influence on 
chromatin conformation (Berger, 2007). The dynamic process of 
acetylation/deacetylation is mediated by two important counteracting 
enzymes: HATs (histone acetyltransferases) and HDACs (histone 
decetylases). Opposing to HATs, HDACs catalyze the removal of acetyl 
groups from histone tails, resulting in compaction of chromatin and 
transcriptional repression (Grozinger and Schreiber, 2002). Deacetylation of 
histone tails by HDAC1 can limit DNA accessibility to the transcriptional 
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activators, thus causing gene silencing. HDAC1 usually cannot directly 
interact with DNA or histone proteins to regulate gene expression. Instead, it 
requires several other components of multi-protein complexes to facilitate its 
accessibility to promoter regions of genes. Some transcriptional repressors 
such as YY-1, RB, and CBF-1 can directly interact with HDAC, whereas 
some other proteins such as nuclear hormone receptors, Mad, and PLZF are 
associated indirectly with HDAC via interactions between this protein and 
additional components like SMRT (silencing mediator of retinoic acid and 
thyroid hormone receptor), and nuclear receptor corepressor (NCoR) of the 
Sin3-HDAC corepressor complex (Grunstein, 1997; Struhl, 1998). HDAC1 is 
recruited by these factors to induce the deacetylation of histone tails and 
therefore causes transcriptional repression. 
1.8.2 Cell development 
1.8.2.1   Cell proliferation 
HDAC1 is involved in cell proliferation. Overexpression of HDAC1 can 
significantly increase cell proliferation and colony formation of MCF-7 cells 
(Hideki et al., 2003). As such, HDAC1 is also essential for embryonic 
development. Knocking out both HDAC1 alleles in mice results in the death 
of embryos before embryonic day 10.5 (E10.5), due to proliferation defects 
and retarded development (Lagger et al., 2002). Aberrant development was 
observed as early as embryonic day 7.5 (E7.5). The loss of HDAC1 in mice 
results in a significant reduction of cellular HDAC activity and specificity in 
histone modifications, as well as an increase in expression of p21 and p27, the 
cyclin-dependent kinase inhibitors, in the embryonic stem cells. HDAC1 can 
39 
 
act with HDAC2 to regulate cell progression. Deletion of both proteins leads 
to a dramatic block in the development of both primary MEFs (mouse 
embryonic fibroblasts) and B-cell. Further studies indicate that the loss of 
HDAC1 and HDAC2 results in the block of cell cycle transition from G1-to-S-
phase and  up-regulating the expression of p21 WAF1/CIP1 and p57Kip2 which can 
inhibit cyclin-dependent kinases (CDK)(Yamaguchi et al., 2010). 
1.8.2.2   Cell differentiation 
HDAC1 is essential for the differentiation of many types of cells. A number of 
knockdown studies have demonstrated that loss of HDAC1 leads to decreased 
differentiation. The presence of HDAC1 is strictly required for the normal 
progression of early B-cell development, as deletion of HDAC1 dramatically 
impairs B-cell differentiation (Yamaguchi et al., 2010). Loss of HDAC1 can 
affect ES cell differentiation by forming smaller embryoid bodies (EBs) with 
preferential differentiation toward mesodermal and ectodermal lineages, which 
reveal the essential role of HDAC1 in embryonic stem cell differentiation 
(Lagger et al., 2002; Dovey et al., 2010). In addition, HDAC1 is involved in 
epithelial, neuronal and muscle cell differentiation (Brunmeir et al., 2009).  
HDAC1 mutant displays severe defects in neuronal retinal in zebrafish. 
HDAC1 has been shown to regulate skeletal muscle differentiation by binding 
to and inhibiting acetylation of MyoD. HDAC1 is also crucial for tumor cell 
differentiation. Lagger et al reported that deficiency in HDAC1 results in 





1.8.2.3   Cell senescence 
Emerging evidence shows that HDAC1 not only positively regulates cell 
proliferation during development (Lagger et al., 2002), but also is involved in 
senescence of cells and tissues (Bandyopadhyay et al., 2007; Bandyopadhyay 
and Medrano, 2003). HDAC1 has been implicated in regulation of senescence 
of a variety of cellular types such as melanoma, human fibroblasts, human 
HeLa cells (Soliman et al., 2008; Willis-Martinez et al., 2010). Over-
expression of HDAC1 triggers dynamic remodeling of chromatin. The 
changes in chromatin therefore induce growth cessation after 8-10 days and 
irreversible growth arrest after three weeks (Bandyopadhyay et al., 2007). 
Further study suggests that the induced senescence by HDAC1 is through pRb 
pathway. Another study by Chuang et al shows that HDAC1 overexpression 
restrains proliferation of cells and induces premature senescence in cervical 
cancer cells through Sp1/PP2A/pRb pathway (Chuang and Hung, 2011). All 
these studies imply the important of HDAC1 in mediation of cellular 
senescence. 
1.8.3 Carcinogenesis 
Since sodium butyrate (NaB), the first identified HDAC inhibitor, was found 
to cause the reversion of the transformed cell phenotype (Ginsburg et al., 
1973; Altenburg et al., 1976; Boffa et al., 1978), several studies have been 
performed to demonstrate that HDAC modulates expression of genes 
implicated in the initiation and progression of cancer (Figure.1.8.3) (Glozak 
and Seto, 2007).  Increased expression of HDAC1 is observed in many cancer 
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types such as prostate (Halkidou et al., 2004), gastric (Choi et al., 2001), 
breast cancer (Hideki et al., 2003).  
 




Moreover, one of the major causes of cancer progression and abnormal gene 
expression is due to the aberrant recruitment of HDAC. The effects of HDAC1 
in cancer is through the deacetylation of both histone and non-histone proteins 
such as tumor suppressor p53. So many of tumors with increased levels of 
HDAC1 corresponds with decreased levels of tumor suppressors such as p53, 
p21 and gelsolin (Ropero and Esteller, 2007). Therefore, either the inhibition 
of HDACs activity or disruption of the HDAC complex has been recognized 
Figure 1.8.3 Histone deacetylation by HDAC influences the 
expression of genes involved in both cancer initiation and progression 
(Taken from Oncogene 2002; 26:5420-5432)
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as a therapeutic strategy to treat various cancers. HDAC inhibitors can 
effectively function in killing tumor cells over normal cells by reversing the 
aberrant epigenetic state. Although the precise mechanisms how HDAC 
inhibitors work in tumor treatment are not well understood, numerous studies 
demonstrated that HDAC inhibitors can promote differentiation, induce 
apoptosis and block cell proliferation, any of which is to thwart the growth of 
cancer cells. Thus, HDAC inhibitors have been developed as anti-cancer drugs 
and are showing encouraging effectiveness in cancer patients. 
1.8.4 Regulation of HDAC1 functions 
HDAC1 function has been shown to be regulated by post-translational 
modifications such as methylation, phosphorylation, acetylation, 
ubiquitination and sumoylation (Jenuwein and Allis, 2001; Lachner and 
Corces, 2004). For example, HDAC1 contains a few potential phosphorylation 
sites and has been found to be phosphorylated (Sengupta and Seto, 2004). 
Published data suggest that phosphorylation can regulate the effects of 
HDAC1 on transcriptional repression, enzymatic activity and functional 
protein-protein interactions. HDAC1 phosphoserine mutation was shown to 
abolish the enzymatic activity and disrupt its interactions with associated 
proteins (Pflum et al., 2001). In addition, sumoylation of HDAC1 is required 
for its cell-cycle arrest, apoptotic response and associated with transcriptional 
repression (Sengupta and Seto, 2004; David et al., 2002). Other than post-
translational modification, it was recently discovered that lipid sphingosine-1- 




1.8.5 HDACs and sumoylation 
Numerous HDACs have been shown to regulate sumoylation of target 
proteins. HDACs usually function in transcriptional repression by removing 
the acetyl groups from substrate proteins. They seem to play very important 
roles in SUMO-mediated transcriptional repression through their recruitment 
to SUMO-modified target proteins. Many SUMO-conjugated transcription 
factors such as p300, Elk1, p68 have been identified to be regulated by 
HDACs (Bouras et al., 2005; Girdwood et al., 2003; Jacobs et al., 2007; Yang 
and Sharrocks, 2004). On the other hand, HDACs are reported to act as E3 
ligases to promote sumoylation of some substrates. HDAC4 enhances 
sumoylation of MEF2 with the similar effect as E3 ligase (Grégoire and Yang, 
2005). Sumoylation of PML triggered by HDAC7 is another example to 
support the idea that HDAC is ablt to promote                                    
sumoylation (Gao et al., 2008).  
 
1.9   G9a (H3K9 methyltransferase) 
In addition to acetylation, histone methylation is a critical post-translational 
modification of histone tails which play significant roles in diverse biological 
processes such as transcriptional regulation, mitosis, cellular differentiation 
and so on. Histone methyltransferases (HMTases) are the primary enzymes 
which are responsible for histone methylation. Many HMTases have been 




1.9.1 Biochemical characters of G9a 
G9a belongs to the histone-lysine methyltransferase (HKMT) family which 
includes Suv39h1, SET9 and Ezh2. It is also known as Bat8, KMT1C and 
NG36 and Euchromatic histone lysine N-methyltransferase 2 (Ehmt2), It is the 
member of the Suv39h subgroup of SET (Su (var) 3-9-Enhancer of zeste-
Trithoras) domain-containing molecules (Jenuwein et al., 1998; Tachibana et 
al., 2001&2002). SET domain which is flanked by 2 cysteine-rich regions was 
shown to be the catalytic domain for methylation of lysine (Rea et al., 2000). 
Besides the SET domain, there are 6 ankyrin repeats which serve for binding 
of other proteins at the carboxyl terminus of G9a (Davis et al., 1991). G9a has 
two isoforms: a long isoform with 1210 amino acids and a short isoform with 
1001 amino acids. G9a is a histone lysine methyltransferase (HKMT) enzyme 
that methylates specific lysine residues within the 28 histone tails and was 
identified to be the second HKMT and can methylate histone H1 and H3 at 
lysine K9 and lysine K27. Like other HMTases, G9a can transfer methyl 
groups to lysine residues of H3 to catalyze methylation. G9a preferentially 
catalyzes H3K9 through mono- or di-methylationly and less efficiently on 
H3K27 (Tachibana et al., 2002; Peters et al., 2003). Di-methylation of histone 
H3 at lysine 9 (H3K9me2) is found to play a critical role for repression of 
gene expression during development and in embryonic stem cells (Tan et al., 
2009; Wen et al., 2009). The methyltransferase G9a is a major H3K9me1 and 
H3K9me2 HKMT of euchromatin, and responsible for catalyzing the H3K9me 
mark as G9a knockout can severely reduce the levels of H3K9me1 and 
H3K9me2. The levels of H3K9me1 are severely decreased in G9a mutant 
mice which display embryonic lethality (Tachibana et al., 2002).  
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1.9.2 Biological functions of G9a 
Compared to other members in Suv39h1 family proteins, G9a has much 
stronger HMTase activity. In addition, it is a key HKMT for H3K9me. Due to 
these facts, G9a plays very critical roles in various biological processes such 
as embryo development, gene expression, immune system, cell differentiation, 
cell-cycle progression and growth (Figure.1.9.2) (Tachibana et al., 
2002&2005; Nagano et al., 2008; Shinkai and Tachibana, 2011). Early studies 
in Shinkai’s lab demonstrate that G9a is required for the development of early 
embryo, as G9a-deficient mouse embryos display serious growth defect and 
early death.  Further studies suggest that the growth retardation of G9a 
deficient mice is due to reduced H3-K9 methylation by loss of HMTase 
activity. Similarly, G9a-deficient ES cells exhibited same phonotype, 
indicating that H3K9 methylation mediated by G9a is crucial for development 
(Tachibana et al., 2002). Besides mediating methylation, G9a is involved in 
regulation of gene expression and functions as a negative regulator of 
transcription (Tachibana et al., 2002; Wagschal et al., 2008; Lin et al., 2012b). 
It can function as a co-repressor by being recruited to some specific proteins 
like transcriptional repressors such as CDP/cut, Blimp-1/PRDI-BF1, and 
REST/NRSF to further modulate their functions. G9a plays an important role 
in immune system. In G9a knockout mice, lymphocyte development is 






1.10 Perspective and Aims of this study  
Various studies have revealed that both Stra13 and Sharp-1 are widely 
expressed in various cell types as well as different tissues and play crucial 
roles in multiple cellular pathways which influence many biological processes. 
However, the underlying mechanisms by which their functions are regulated 
are not clear. SUMO modification of many transcription factors usually 
correlates with transcriptional repression. In this study, we provide evidence 
that SUMO modification of the bHLH proteins Stra13 and Sharp-1 can 
significantly regulate their transcriptional activities and therefore influence 
Figure 1.9.2 Multiple biological roles of G9a (Modified from Genes & 
Development 2011; 25: 781-788)
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their biological functions. Furthermore, we demonstrate that the effects of the 
SUMO modification on these two transcription factors can be mediated 
through the recruitment of co-repressors HDAC1 for Stra13 and G9a for 
Sharp-1. 
Previous studies from our lab and others have demonstrated that Stra13 
associates with the co-repressor HDAC1 through its repression domain at C-
terminal (Sun and Taneja, 2000) and regulates transcriptional repression of 
specific target genes (Sun and Taneja, 2000; Fujimoto et al., 2007; Ivanov et 
al., 2007). However the mechanism by which HDAC1 regulates Stra13-
dependent biological functions remains unclear. Our studies show that there 
are two potential SUMO motifs (Lysine 159 and 279) which are located at the 
C-terminal of Stra13 sequence, therefore, the first part of this study aims to 
investigate how sumoylation modulates activities of Stra13. Specifically, this 
work addresses the following questions: 
 To examine whether Stra13 is SUMO modified;  
 Is Stra13-mediated cell growth is SUMO-dependent?  
 
Sharp-1 was previously shown to inhibit myogenic differentiation and 
interacts with the co-repressor G9a to inhibit differentiation of skeletal muscle 
precursor cells by our lab (Azim et al., 2004; Ling et al., 2012b). However, the 
molecular mechanism by which it recruits G9a is not understood. Hence, the 
second part of this study aims to investigate the following questions: 
 Is Sharp-1 is SUMO modified? 





This study provides new mechanistic insights into SUMO-dependent 
regulation of Stra13 and Sharp-1 in mediating transcriptional activity, cell 










































2.1.   Cell culture  
2.1.1 Cell lines  
 HEK293 (Human Embryonic Kidney 293 cells), 10T1/2, MCF7and Phoenix 
cells were cultured in Dulbecco’s Modified Eagle’s Medium (DMEM) 
supplemented with 10% FBS (fetal bovine serum) (Gibco, Life Technologies, 
Carlsbad, CA). NIH3T3 (Mouse embryonic fibroblast cells), COS-7 (Green 
Monkey Kidney Fibroblast cells) cells were cultured in DEME with 10% calf 
serum (Hyclone Laboratories Inc, Utah ) and 10% bovine serum (Gibco) 
respectively. C2C12 was cultured in DMEM with 20% fetal bovine serum 
(Hyclone). K562 cells was cultured in Roswell Park Memorial Institute 
medium (RPMI) with 10% fetal bovine serum (Gibco). 1x antibiotic-
antimycotic was added to all the mediums. MEFs (Mouse Embryonic 
Fibroblasts) were cultured as described (Sun et al., 2001). The cells were 
maintained in an incubator at 370C in a 5% CO2 humidified atmosphere.  
2.1.2   Transient transfection 
Twenty-four hours before transfection, cells were counted using a 
hemocytometer and plated at a density of 1.5x106 cells/10-cm-diameter plate; 
5x105 cells /6-well plate; or  2x104  cells per well in 24-well plates. For the 
overexpression of plasmids, the cells were transfected using LipofectamineTM 
2000 (Invitrogen, Grand Island, NY) or Fugene 6 (Roche Applied Science, 
Mannheim, Germany) according to the manufacturer’s instructions. For the 
transfection of plasmids in Phoenix cells, the Calcium Phosphate Transfection 
Kit (Invitrogen) was used according to manufacturer’s instructions. Each 




2.1.3 Cell differentiation assays 
C2C12 cells were co-transfected with a 1:9 ratio of an expression vector for 
Sharp-1 or Sharp-1 2KR and pBabe (which confers resistance to puromycin). 
24 hours after transfection, cells were selected in medium containing 2 ug/ml 
puromycin for two days. Selected cells were cultured at high density (80%-
90% confluent) in growth medium (GM) for a day and then switched to 
differentiation medium (DM, containing DMEM with 2% horse serum and 1x 
antibiotic-antimycotic) for another one to two days.  
2.1.4   Myogenic index  
 
Myogenic index was determined by calculating the ratio of nuclei in myosin 
heavy chain (MHC) -stained myotubes over total nuclei. At least 600 nuclei 
were counted from three different fields. Values are reported as means with 
standard deviation (shown as error bars).  
 
2.2   Plasmids and Mutagenesis 
Flag-mPIAS1, Flag-mPIAS3, Flag-mPIASxa, Flag-mPIASy, SUMO1, SENP1 
and pD1luc harboring the cyclinD1 promoter were kindly provided by Dr 
Martin B. Lee (Lee et al., 2005) and M.Hinz (Hinz et al., 1999).  Plasmids 
FLAG-G9a (1001 aa) and MyoD were kindly provided by Dr. Martin J. Walsh 
(Mt Sinai School of Medicine, New York, USA).Flag-HDAC1 and Flag-
PCAF in pCS2 vector have been described (Sun et al., 2000). pCS2-Myc-
Stra13 was  produced by PCR amplification using the primers in Table 2.1. 
The PCR product was TA-cloned into pCRII (Invitrogen) and then sub-cloned 
into the EcoR1 site of pCS2. pBabe-Myc-Stra13 and pBabe-Myc-Stra13 2KR 
were generated from pCS2-Myc-Stra13 and pCS2-Myc-Stra13 2KR.  
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To generate the Stra13 SUMO mutants (K279R, K159R and 2KR), and Sharp-
1 SUMO mutants (K240R, 2KR), QuickChangeTM site-directed mutagenesis 
kit (Stratagene, La Jolla, CA) was used to mutate single (K279R & K159R; 
K240R) or double (2KR) amino acid within the SUMO motifs of Stra13 and 
Sharp-1. The mutants were generated from pCS2-Myc-Stra13 and pCS2-Myc-
Sharp-1 using the primers listed in Table 2.1. The entire cDNA was sequenced 
to confirm the presence of the directed mutations.  
 
2.3    Immunoprecipitation, western blotting and antibodies 
2.3.1   Protein extraction and quantification 
24-48 hours post-transfection, cells were washed twice in cold 1xPBS and 
then harvested in 50 mM Tris-HCl (pH8.0), 50 mM NaCl, 1 mM EDTA, 0.1% 
Triton X-1000, 0.5 mM PMSF (phenylmethylsulfonyl fluoride) and protease 
inhibitors (Roche). For detection of sumoylation, 20mM NEM (N-
ethylmaleimide) (Sigma, St Louis, MO) was added to the lysis buffer to inhibit 
SUMO isopeptidases. Lysed cells were scraped and transferred to a tube for 
incubation at 40C for 45 minutes. The samples were then centrifuged at 13,000 
RPM for 30 minutes at 40C and then the supernatant was collected into the 
microcentrifuge tubes as cell lysates. Protein concentrations were determined 
by using the Bradford method (Bio-Rad, Hercules, CA). 
2.3.2   Immunoprecipitation (IP) 
For immunoprecipitation of overexpressed proteins, lysates were directly 
incubated with anti-c-Myc-agarose beads or Flag-agarose beads (Sigma) in 
pull down buffer while rotating overnight at 40C. For immunoprecipitation of 
endogenous proteins Stra13 and HDAC1, 20ul of A/G agarose beads (Santa 
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Cruz, Dallas, TX) was first incubated with 3ug of anti-Stra13 (Novus 
Laboratories, St.Louis, Missouri), anti-Sharp-1 (Santa Cruz) or anti-HDAC1 
(Upstate, Charlottesville, VA) antibodies on a rotator for 4-6 hours at 4oC. 
After incubation, the mixture was washed with RIPA lysis buffer for three 
times, and then centrifuged at low speed for 1 minute. The supernatant was 
removed and cell lysates were added to the pallets with rotating at 40C 
overnight. The next day, the immunoprecipitates were washed with RIPA lysis 
buffer for four times and boiled in 25ul of 2 x loading sample buffer, then the 
samples were resolved and analyzed by western blotting. 
2.3.3   Western blotting 
Equal amounts of each sample was mixed with 5x loading buffer (10% SDS, 
50% glycerol, 0.01% bromophenol blue, 50 mM Tris pH6.8), denatured at 
950C for 5-10 minutes and then loaded and separated on 8 or 10% 
polyacrylamide gel. After electrophoresis, the gel was set up to be transferred 
onto nitrocellulose membrane (Amersham Biosciences, Little Carlsbad, CA) at 
180 mA for 1 hour. The membrane was blocked in 5% non-fat milk in PBST 
(1XPBS, 0.1% Tween-20) for 1 hour at room temperature on a shaker. After 
blocking, the membrane was incubated with primary antibodies diluted in 3% 
non-fat milk in PBST (1XPBS with 1% Tween) for 1 hour at room 
temperature or overnight at 40C. The membrane was then washed in 1xPBST 
for 5 minutes thrice, and incubated with either horseradish-peroxidase-
conjugated anti-rabbit or anti-mouse IgG secondary antibodies (Sigma). 
Western blots were incubated with ECL Plus western blotting detection 
reagents (Amersham Biosciences) for 1 minute at room temperature, and then 
developed in the Kodak X-ray Processor. 
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2.4   Colony suppression, Cell cycle analysis, and Proliferation assays 
NIH3T3 cells were transfected with Myc-tagged Stra13 or Stra13 2KR along 
pD503 or pBabe that confers resistance to puromycin. Control cells were 
transfected with empty vector and pD503. 24 hours after transfection, half of 
the cells were collected for western blotting analysis to check the expression 
level of proteins, and the remaining cells were cultured in the presence of 1.2 
ug/ml puromycin (Sigma) for selection for three days. Selected cells were used 
for the following assays: 
2.4.1   Colony formation assays 
 Colony assays were done as described (Sun and Taneja, 2000). Briefly, the 
selected cells were seeded at a density of 1x103cells/10-cm plate. Ten days or 
two weeks later, the cells were washed with 1xPBS two times and fixed with 
70% ethanol. After two times of washing with 1XPBS, the colonies were 
stained with 0.02% crystal violet solution and washed with water. The stained 
colonies were photographed. For quantification, the stained colonies were 
extracted in 1% SDS solution and the absorbance was read at 570 nm. 
2.4.2   Cell cycle assays 
Selected cells were plated at a density of 5x105/10-cm plates. 24 hours later, 
cells were washed in 1xPBS, trpysinized, and collected. Both the live adherent 
and dead floating cells were collected and centrifuged at 2500 rpm for 5 
minutes. They were washed with 1xPBS, fixed with cold 70% ethanol. Fixed 
cells were resuspended in 500ul propidium iodide (PI) staining solution (0.1% 
Triton-X, 0.2mg/ml RNaseA, 0.02mg/ml propidium iodide, in 1xPBS) and 
incubated for 30 minutes at room temperature in the dark. 
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The PI-stained cells were filtered through a 40um filter before being run 
through a Beckman Counter Epics Altra at the Flow Cytometry Unit. Twenty 
thousand cells were acquired and analyzed for each sample to generate a cell 
cycle profile in flow cytometer (Becton Dickinson, Mountain View, CA). 
Analysis was done using the WINMDI software. 
2.4.3   Cell proliferation/Viability (MTT) assay 
Selected NIH3T3 cells were seeded at a density of 1x104 per well in 6-well 
plates in triplicates. Attached cells were trypsinized and proliferation rate was 
measured by counting cells daily over a period of five days. 
Alternatively, 3000 cells were seeded in 96-well plates and 72 hours later, 
MTT assays were performed by using MTT cell proliferation assay kit 
(Invitrogen) according to manufacturer’s instructions. 
 
2.5   Immunofluorescence 
COS7 cells were used to examine the sub-cellular localization of wild type 
Stra13 and SUMO mutants, as well as wild type Sharp-1 and its SUMO 
mutants. Cells were seeded at a density of1x104 cells/well in 6-well plates. 24 
hours later, cells were transfected with Myc-Stra13 and Myc-Stra13 2KR, or 
additionally co-transfected with SUMO1 as well as the empty vector pCS2 as 
the control in duplicate. For Sharp-1 localization, COS7 cells were transfected 
with Myc-tagged Sharp-1 and its mutant Myc-tagged Sharp-1 2KR, alone or 
together with SUMO1. 48 hours after transfection, cells were fixed with 4% 
formaldehyde for 10 minutes. Three subsequent wash steps were performed in 
1XPBS. Then the cells were permeabilized in 1xPBS containing 0.3% Triton 
X-100 for 30 minutes, and blocked in 1xPBS containing 3% BSA for 1 hour. 
56 
 
After that, cells were incubated with primary antibody (mouse anti-Myc, 
1:100) and detected with secondary antibody coupled with Texas-red (1:250, 
Invitrogen). Slides were mounted in Vectashield (Vector Laboratories, 
Burlingame, CA) supplemented with DAPI (4’, 6’-diamidino-2-phenylindole) 
to identify nuclei. Cells were visualized on a Zeiss LSM 510 META confocal 
laser-scanning microscope. 
 
2.6   Luciferase assays 
HEK293, 10T1/2 or NIH3T3 cells were seeded at a density of 1x104 cells per-
well in 24-well plates. 24 hours later, cells were transfected with different 
promoter reporters (pD1luc, 9E-TATA-Luc or pMyogLuc ) along with Stra13 
or Sharp-1, Stra13 2KR or Sharp-1 2KR, SUMO1, SENP1 with the  indicated 
amounts in the figures along with 5ng of Renilla luciferase as the internal 
control. Empty expression vector was added to ensure the same amount of 
total DNA was transfected. 48 hours post-transfection, medium was aspirated 
off and the cells were washed once with 1xPBS. The PBS was then removed 
and 100ul of 1xLuciferase lysis buffer (Promega, Fitchburg, WI) was added to 
the cells and the mixture was incubated on a shaker at room temperature. After 
15 minutes, the lysate were transferred to 1.5 ml eppendorf tubes. 20ul of the 
cell lysates were used to measure the luciferase activity by the Dual-
Luciferase Reporter Assay system (Promega) on Tecan microplate reader and 
analyzed using Magellan 6 software. All transfections were performed in 
triplicates and repeated at least twice. Values were reported as means with 
standard deviation (SD). 
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In knockdown cells, siRNA knockdown cells were transfected with cyclinD1 
promoter reporter pD1luc, Stra13 with indicted amount in figure along with 
5ng of Renilla Luciferase. 24 hours later, Luciferase reporter assay was 
performed. 
 
2.7 Senescent cells histochemical staining assay (SA-β-Galactosidase 
staining assay) 
Selected cells were seeded at a density of 1x103cells/well in 6-well plates. 7 
days later, SA-β-Galactosidase staining assay was performed according to the 
manufacturer’s instructions (Sigma).  Briefly, cells were washed with 1 x PBS 
twice and fixed with 1x Fixation Buffer (2% formaldehyde, 0.2% 
glutaraldehyde, 7.04 mM Na2HPO4, 1.47 mM KH2PO4, 0.137 M NaCl, and 
2.68 mM KCl) for 10 minutes at room temperature. Cells were then washed 
three times with 1 x PBS and stained with SA-β-Galactosidase staining 
solution (1mg/ml 5-bromo-4-chloro-3-indolyl-β-D-galactopyranoside, 40 mM 
sodium phosphate (PH6.0), 5 mM potassium ferrocyanide, 5 mM postassium 
ferricyanide, 150 mM NaCl, and 2 mM MgCl2) at 370C without CO2  
overnight. Plates were sealed with parafilm and kept at 40C for microscopy. 
Senescent cells were visualized on microscope and photographs were taken to 
calculate the percentage of senescent cells. 
 
2.8   Retrovirus production and infection 
Phoenix cells were seeded at a density of 1.5x106 cells/10-cm plate. 24 hours 
later, cells were transfected with pBabe-puro based plasmids Myc-Stra13 and 
Myc-Stra13 2KR along with control vector by using Calcium Phosphate 
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transfection kit (Invitrogen) according to the manufacturer’s instructions. 24 
hours after transfection, the medium was changed to NIH3T3 cell growing 
medium (DMEM supplemented with 10% BS and 1x antibiotic-antimycotic). 
The 1st and 2nd viral supernatants were collected on Day 4 and Day 5. The 
collected supernatants were filtered with 0.45um filters. 24 hours before 
infection, NIH3T3 cells were plated at a density of 0.3x106 cells/10-cm plate. 
The cells were infected with virus containing medium in the presence of 
8ug/ml polybrene for 8 hours. After that, the medium with virus was removed 
and the cells were washed 3 times with growing medium. 24 hours later, the 
infected cells were selected with 1.2ug/ml puromycin for three days before 
plating for different assays 
 
2.9   Drug treatment and total RNA isolation 
The stable NIH3T3 cells with virus infection were synchronized in mitosis by 
adding nocodazole at a final concentration of 500ng/ml. After 16 hours, 
nocodazole was removed by washing with growing medium 2 times. Cells 
were then re-plated in 10-cm cell culture dishes and 24 hours later, cells were 
washed in 1xPBS and harvested by trypsinization. Total RNA was extracted 
from cells using TRIZOL according to the manufacturer’s instructions 
(Invitrogen). The total RNA was eluted in 50 ul of RNase-free water and 
quantified at 260 nm. 
 
2.10   Quantitative Real-time PCR (Q-PCR) 
Genomic DNA was eliminated by treatment with TURBO DNase (Ambion, 
Austin, TX) from total RNA and cDNA synthesis was carried out using AMV 
59 
 
Reverse Transcriptase (Promega) according to manufacturer’s instructions. 
1ug of RNA and 1ul of oligo (dT) primer was used for cDNA synthesis. For 
subsequent PCR, 1 out of 25ul total volume was used. Primers sequences are 
shown in Table 2.3. Q-PCR was performed using LightCycler 480 SYBR 
Green I master (Roche) according to manufacturer’s specification on the 
Roche LightCycler 480 machine. Each sample was set up in triplicates in 
special 96 well plates (Roche).  
 
2.11   Chromatin immunoprecipitation (ChIP) assay  
For NIH3T3 cells, after retrovirus production and infection followed by 
puromycin selection, 2x106   of the selected cells were seeded in 10-cm plates. 
24 hours later, cells were fixed in 1% formaldehyde at 370C for 10 minutes, 
then washed in 1xPBS and scraped off from plates. ChIP assays were 
performed as described (Ling et al., 2012a). The cells were fragmented by 
sonication after they were resuspended in SDS lysis buffer (50 mM Tris-Cl 
pH8.1, 1% SDS, 10 mM EDTA, 1 mM PMSF, 1 ug/ml aprotinin, 1 ug/ml 
pepstatin A). The chromatin were immunoprecipitated with 2-3 ug of anti-
DEC1 (Bethyl Laboratories, Montgomery, TX) and H3K9K14ac (histone 3 
acetylated lysine 9 and lysine 14) antibodies (Upstate). The cross-links were 
heat-reversed at 650C and DNA was extracted using phenol-chloroform. DNA 
was amplified and quantified by Q-PCR by using the primers specific to 
cyclinD1 promoter sequence and β-actin as shown in Table 2.4.  
Each reaction was carried out in triplicate and values were normalized to β-
actin. The results were presented as average with standard deviation (shown as 
error bar).  
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2.12   HDAC1Knockdown with siRNA 
NIH3T3 cells were seeded in a density of 1.5x106 cells/10-cm-diameter plates 
or 3x104 cells /24-well plates. 24 hours later, cells were transfected with 
100nM siRNA specific for mouse HDAC1 (Ambion), or with control 
scrambled siRNA using Lipofectamine RNAiMAX (Invitrogen). 24 hours 
post-transfection, Myc-Stra13 and Myc-Stra13 together with SUMO1 were 
transfected into siRNA and control scrambled siRNA transfected cells 
respectively. 24 hours later, cells were harvested and subjected to 
immunoprecipitation with anti-c-Myc agarose beads and western blot analysis 
with anti-SUMO1 antibody. The efficiency of knockdown was determined 
using anti-HDAC1 antibody. 
 
2.13   Statistical analysis 
Error bars indicate mean±standard deviation (S.D.). Statistical analysis was 
performed by Student’s t-test. P-values were indicated with different degrees 
of significance as * (p < 0.05), ** (p < 0.01) or *** (p < 0.001) where p <0.05 












Table 2.1    List of primers used for PCR  




Myc-Stra13 antisense GAATTCTTAGTCTTTGGTTTCTAAGTT 
Myc-Stra13 K279R sense GTCAGCACAATTAGGCAAGAATCCGA
A 
Myc-Stra13 K279R antisense TTCGGATTCTTGCCTAATTGTGCTGAC 
Myc-Stra13 K159R sense CAGTACCTGGCGAGGCATGAGAACAC
T 
Myc-Stra13 K159R antisense AGTGTTCTCATGCCTCGCCAGGTACTG 




5’-GGG TGG CTC CTG TCG GAC GGC 
CGC GCG-3’ 












Table   2.2   List of antibodies used in western blotting.  
Antibody Company Source Dilution 
Myc Roche Mouse monoclonal 1:2,000 
Flag Sigma Mouse monoclonal 1:3,000 
SUMO1 Zymed Mouse monoclonal 1:150 
β-actin Sigma Mouse monoclonal 1:20,000 
p53 Santa Cruz 
Biotechnology Inc 
Mouse polyclonal 1:500 
DEC1 Bethy Laboratories Rabbit polyclonal 1:1000 
Stra13 Novus Laboratories Rabbit polyclonal 1:1000 
HDAC1 Upstate Mouse monoclonal 1:1000         
p21 Santa Cruz 
Biotechnology Inc 
Rabbit polyclonal 1:500 
p16 Abcam Rabbit polyclonal 1:1000 
Rb Santa Cruz 
Biotechnology Inc 
Mouse monoclonal 1:200 
Troponin T Sigma Mouse monoclonal 1:3000 
Sharp-1 Santa Cruz 
Biotechnology Inc 
Rabbit polyclonal 1:500 








    
Table 2.3    List of primers used for Q-PCR  
Primer Name Primer sequence 
Cyclin D1 sense  5’-
AAGTGCGTGCAGAAGGAGATTGTG-
3’ 
Cyclin D1 antisense 5’-
TCGGGCCGGATAGAGTTGTCAGT-3’ 
p21 sense 5’-GCAGCCGCGAGGTGTGAGC-3’ 
p21  antisense 5’-ACGGGACCGAAGAGACAACG-3’ 
Cyclin B1  sense 5’-CGGTGAATGGACACCAACTCTG-
3’ 
Cyclin B1 antisense 5’-CTGTGCCAGCGTGCTGATCT-3’ 
Cyclin E1 sense 5’-
TGTCCTCGCTGCTTCTGCTTTGTATC
AT-3’ 
Cyclin E1 antisense 5’-
GGCTTTCTTTGCTTGGGCTTTGTCC-
3’ 
GAPDH sense 5’-ATCAACCGGGAAGCCCATCAC-3’ 






Table 2.4    List of primers used for ChIP 
Primer Name Primer sequence 
Cyclin D1 promoter sense 5’-GAGAGCTTAGGGCTCGTCTG-
3’ 






















SUMOYLATION IN REGULATION OF 
STRA13 TRANSCRIPTIONAL ACTIVITY 









3.1 Stra13 is SUMO conjugated in vivo 
3.1.1 Two potential SUMO sites are located in Stra13  
Post-translational modification of transcription factors is a mechanism widely 
used to achieve dynamic regulation of their transcriptional activities. Among 
these, sumoylation has been identified to modify an increasing number of 
transcription factors (Muller et al., 2004; Gill, 2005; Geiss-Friedlander and 
Melchior, 2007). Stra13 is a member of the bHLH-O transcriptional repressor 
subfamily. SUMO is usually covalently attached to its substrates at a lysine 
residue in a ψ KXE sequence (where ψ is a large hydrophobic residue, X 
represents any amino acid and E is glutamic acid). Previous studies in our lab 
demonstrated that the co-repressor HDAC1 interacts with the C-terminal 
region of Stra13 spanning amino acid residues 111-343 (Sun and Taneja, 
2000). Examination of the Stra13 amino acid sequence revealed two potential 
sumoylation motifs. One is at lysine 279(IKQE), the other is at lysine 
159(AKHE). Lysine 279 is preceded by a large hydrophobic amino acid while 
lysine 159 is preceded by a small hydrophobic amino acid. Alignment of these 
two motifs from several species including human, mouse, rat, zebrafish and 
Drosophila melanogaster revealed that lysine K279 within IKQE motif is 
phylogenetically conserved, whereas lysine K159 within AKHE is less 
conserved through various species (Figure 3.1.1). These two motifs are located 












3.1.2 Stra13 is covalently modified by SUMO-1 at lysine 279 
The observation that the conserved putative sumoylation motifs are within the 
repression region of Stra13 led us to speculate that sumoylation may play an 
important role in regulating the transcriptional activity and biological 
functions of Stra13. In light of these observations, we therefore examined 
whether Stra13 undergoes sumoylation. We transiently transfected HEK293 
cells with constructs encoding empty vector pCS2 or wild type Myc-Stra13 in 
the absence or presence of SUMO1. At 48 hours post-transfection, cells were 
lysed in the presence of 20mM N-ethyl-maleimide (NEM), an inhibitor of 
SUMO hydrolases. The lysates were immunoprecipitated with anti-c-Myc 
Figure 3.1.1 Schematic representation of the Stra13 domain 
structure. (upper panel). The basic and HLH domains are shown along 
with three α-helices in the C-terminal repression domain. Potential 
sumoylation acceptor lysines at 159 and 279 (K159 and K279) are 
indicated. Numbers indicate amino acid residues in the mouse Stra13 
cDNA. Alignment of Stra13 cDNA from human, mouse, rat, zebrafish 
and Drosophila melanogaster revealed a highly conserved SUMO 
consensus motif IKQE, and a somewhat less conserved motif AKHE that 
are highlighted. K159 and K279 are indicated by arrowheads (lower 
panel).  
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agarose beads followed by western blotting with anti-SUMO1 antibody 
(Figure. 3.1.2). In the presence of SUMO1, a putative sumoylation band was 
detected, corresponding to the sumoylated Stra13 (Figure 3.1.2, lane 3). 
Sumoylation is a reversible chemical modification, and some SUMO-specific 
proteases can cleave the isopeptide bond between SUMO and the substrate 
lysine residues to cause desumoylation. So to further determine whether the 
slower migrating band corresponds to sumoylated Stra13, we co-transfected 
the cells with the Sentrin specific protease1 (SENP1), which is able to remove 
SUMO conjugates from substrates, together with Myc-Stra13 and SUMO1. 
Our results showed that in the presence of SENP1, sumoylation of Stra13 was 















Figure 3.1.2 Stra13 is sumoylated in vivo.  Cells were co-
transfected with Myc-Stra13, SUMO1 and SENP1 as indicated. 
Lysates were immunoprecipitated with Myc-agarose beads followed 
by immunoblotting with anti-SUMO1 antibody. Input shows 




3.1.3 Identification of two sumoylation sites in Stra13 
As shown in Figure 3.1.1, Lys 279 and Lys 159 of Stra13 are putative 
sumoylation sites. To determine whether K159 and K279 serve as acceptor 
sites for sumoylation, we generated lysine (K) to arginine (R) point mutants at 
each site individually (Stra13 K159R and Stra13 K279R respectively) and 
together (2KR) by site-directed mutagenesis. To test the abilities of the 
mutants to be sumoylated, HEK293cells were co-transfected with Myc-tagged 
Stra13 wild type or its mutants together with SUMO1. The cell lysates were 
immunoprecipitated with anti-c-Myc agarose beads and detected by western 
blotting using anti-SUMO1 antibody (Figure 3.1.3). The result revealed that in 
the presence of SUMO1, both Stra13 wild type and Stra13 K159R mutant 
were sumoylated. In contrast, neither Stra13 K279R nor Stra13 2KR were 
sumoylated, suggesting SUMO conjugation occurs predominantly at K279, 














3.1.4 Stra13 sumoylation is enhanced by PIAS3 and PIAS1 
Among all the E3 SUMO ligases, the PIAS protein family has been best-
characterized and shown to be able to significantly enhance the level of 
sumoylation of the target proteins (Kotaja et al., 2002). To examine whether 
PIAS proteins can modulate sumoylation of Stra13, HEK293 cells were co-
transfected with Myc-Stra13, SUMO1 and Flag-tagged proteins from the PIAS 
family such as PIAS1, PIAS3, PIASxa and PIASy. After immunoprecipitation 
with anti-c-Myc agarose beads, the proteins were subjected to western blotting 
analysis with anti-SUMO1 antibody to detect Stra13 sumoylation. The 
expression of Stra13 and PIAS proteins was detected with anti-Myc and anti-
Flag antibodies (Figure 3.1.4). As shown in the figure, all the PIAS proteins 
are almost equally expressed, both PIAS3 and PIAS1 enhance Stra13 
sumoylation, whereas expression of PIASxa and PIASy do not show such 
stimulation (Figure.3.1.4). Thus, we conclude from this result that PIAS1 and 
PIAS3 can act as E3 SUMO ligases and promote the sumoylation of Stra13. 
 
Figure  3.1.3  Stra13 is sumoylated at lysine279. Cells were co-
transfected with Myc-Stra13, or point mutants (Stra13 K279R, Stra13 
K159R, Stra13 2KR) together with SUMO1. Cell lysates were 
immunoprecipitated with Myc-agarose beads and the immumoprecipitates 










3.1.5 Stra13 is sumoylated endogenously 
To validate the findings that Stra13 can be sumoylated, we further examined 
whether Stra13 can be post-translationally modified by the endogenous 
sumoylation machinery. To test this possibility, some Stra13-positive cell lines 
such as MCF-7 and K562 were used. After showing expression of Stra13 in 
these two cell lines (Figure 3.1.5A & B), lysates were immunoprecipitated 
with anti-Stra13 antibody. The subsequent western blotting  analysis probed 
with anti-SUMO1  antibody revealed a slower-migrating form of Stra13 that 
was dependent on the presence of the SUMO protease inhibitor, N-
ethylmaleimide (NEM), confirming their identities as SUMO1-modified 
endogenous Stra13 (Figure 3.1.5 A & B).   
 
 
Figure 3.1.4 Stra13 sumoylation is enhanced by PIAS3 and PIAS1. 
Cells were co-transfected with Myc-Stra13 and SUMO1 along with 
Flag-PIAS1, PIAS3, PIASXa or PIASy as indicated. Cell lysates were 
immunoprecipitated with Myc-agarose beads and the 
immumoprecipitates were subjected to western blotting with anti-












3.1.6 Endogenous Stra13 is SUMO conjugated in fibroblast cells 
Previous studies in the lab indicate that endogenous Stra13 expression is up-
regulated during growth arrest induced by TSA (Sun and Taneja, 2000). To 
confirm that the modification by Stra13 sumoylation in fibroblasts is 
physiologically relevant, we sought to determine whether the growth 
suppression induced by TSA is related to sumoylation of endogenous Stra13. 
Figure 3.1.5 Stra13 is sumoylated endogeneously. (A) Cell lysates 
of K562 cells extracted in the absence (-) or presence (+) of 20mM N-
ethylmaleimide (NEM) were immunoprecipitated (IP) with antibody to 
Stra13 and immunoblotted with anti-SUMO1 antibody. Control 
western blots are shown of input lysate.  (B) Cell lysates from MCF7 
cells extracted in the absence (-) or presence (+) of 20mM N-
ethylmaleimide (NEM) were immunoprecipitated (IP) with antibody to 
Stra13 and immunoblotted with anti-SUMO1 antibody. Control 
western blots are shown of input lysate.   
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NIH3T3 cells were treated with 1uM TSA. 24 hours later, cells in the absence 
or presence of TSA treatment were harvested and 1.5 mg NEM-treated lysates 
were immunoprecipitated with polyclonal anti-Stra13 antibody. The 
subsequent western blotting with anti-SUMO1 antibody reveals that Stra13 is 
SUMO modified at the endogenous level and Stra13 sumoylation was indeed 
enhanced in TSA treated cells (Figure. 3.1.6).  
 
 







3.2 Stra13 sumoylation is required for its anti-proliferative effects 
3.2.1   Sumoylation impacts Stra13-mediated growth arrest 
Stra13 has been shown to mediate cell growth suppression in a number of 
cell types (Sun and Taneja, 2000; Seimiya et al., 2002; Qian et al., 2008). 
Our primary studies indicated that the sumoylation sites of Stra13 were 
located within its repression region which is associated with growth arrest. 
Figure 3.1.6 Sumoylation of Stra13 in fibroblast cells NIH3T3 
cells were left untreated (-) or treated (+) with TSA with the final 
concentration of 1 uM. 24 hours later, endogenous Stra13 was 
immunoprecipitated with anti-DEC1 antibody and detected with 
anti-SUMO1 antibody.  
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To explore the biological relevance of sumoylation on the biological 
functions of Stra13, we therefore examined whether sumoylation can impact 
Stra13-mediated growth arrest by performing colony formation assay. 
NIH3T3 cells were co-transfected with empty vector pCS2, wild type 
Stra13, or Stra13 double mutant (2KR) along with pD503, which confers the 
resistance to puromycin. 24 hours post-transfection, half of the cells were 
collected for western blotting analysis with anti-Myc antibody which 
showed equivalent expression of Stra13 and Stra13 2KR (Figure 3.2.1.A). 
The remaining cells were selected by addition of 1ug/ml puromycin and 
after 3 days, seeded at a low density in 10-cm plates. Two weeks later, 
colonies were fixed and stained with 0.1% crystal violet. Consistent with our 
previous studies (Sun and Taneja, 2000), overexpression of Stra13 resulted 
in significant reduction in colony numbers compared with vector-transfected 
cells (Figure 3.2.1.B, C). Interestingly, in contrast to wild type Stra13, 
Stra13 2KR mutant was unable to inhibit colony formation. As shown in 
Figure 3.1.1.B & C, the colony numbers in Stra13 2KR expressing cells are 
not much changed compared with control cells (Figure 3.2.1.B, C). These 
results strongly implicate that sumoylation is involved in the regulation of 



















3.2.2   Sumoylation is essential for Stra13-dependent growth inhibition  
SUMO conjugation is a dynamic and reversible modification which is 
reversed by SUMO-specific proteases such as SENPs (Best et al., 2002). We 
have shown that SENP1 is able to desumoylate Stra13 (Figure 3.1.2).  To 
Figure 3. 2.1 Mutation of sumoylation sites abrogates Stra13-mediated 
growth arrest. (A) NIH3T3 cells were cotransfected with Myc-Stra13 or 
Stra13 2KR together with a puromycin resistance plasmid. Empty vector 
(pCS2) was transfected in control cells (Vector). Stra13 and Stra13 2KR 
expression was determined by western blotting using anti-Myc antibody. (B-
C) Colony forming assays were performed with control, Stra13 and Stra13 
2KR cells. 14 days later, colonies were stained with crystal violet. Data is 
representative of three independent experiments (B). Crystal violet dye was 
extracted and the absorbance measured at a wavelength of 570 nm. The error 




confirm the impact of sumoylation on Stra13-mediated growth inhibition, 
we asked whether the removal of Stra13 sumoylation by SUMO protease 
can recapitulate the phenotype of Stra13 2KR expressing cells. To test this 
possibility, we co-expressed SUMO protease SENP1 along with equivalent 
levels of Myc-tagged Stra13 and Stra13 2KR in NIH3T3 cells (Figure. 3.2.2 
A) and performed colony formation assays. Cells expressing Stra13 exhibit 
the significant reduction in colony numbers compared to vector-transfected 
cells. As expected, co-expression of SENP1 reversed the inhibitory effect of 
Stra13 on cell growth, whereas Stra13 2KR was insensitive to SENP1 
(Figure 3.2.2 B-C). These results confirm that sumoylation of Stra13 is 
indeed critical in mediating growth arrest in fibroblast cells and Stra13-
mediated growth arrest is SUMO- dependent. 
 
  






















3.3 Mechanism underlying Stra13-mediated cell growth inhibition 
Stra13-mediated growth suppression has been shown to be related to various 
types of anti-proliferative effects in numerous cell lines. These anti-
proliferative effects of Stra13 may be induced by the inhibition of cell 
proliferation, induction of cell cycle arrest, and increasing apoptosis (Sun 
and Taneja, 2000; Qian et al., 2008; Bhawal et al., 2011). The inability of 
Figure 3.2.2 Sumoylation is essential for Stra13-dependent growth 
inhibition. (A) Lysates of NIH3T3 cells transfected with equivalent 
levels of Myc-Stra13, Stra13 2KR together with SENP1 were 
immunoblotted with anti-Myc antibody. (B-C) 14 days after selection, 
colony assays were performed and colonies were stained with crystal 
violet. Representative plates are shown (B). The mean relative 
absorbance after extraction of crystal violet stain from plates in shown 
in C. Error bars indicate mean± SD. 
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Stra13 2KR mutant to mediate growth suppression in our data indicated that 
sumoylation may be involved in the anti-proliferative effects of Stra13. To 
investigate the underlying mechanisms how sumoylation regulates Stra13-
mediated growth inhibition, some related assays for measurement of cell 
growth or proliferation rate, cell cycle profile and apoptosis were carried out.  
3.3.1   Sumoylation is involved in the inhibition of cell proliferation 
mediated by Stra13 
To examine whether sumoylation can regulate Stra13-related inhibition of 
cell proliferation, NIH3T3 cells expressing empty vector, Stra13 and Stra13 
2KR were seeded at 1x104 cells/well in 6-well plates. Attached cells were 
counted over a 5-day period to measure cell proliferation rates. Consistent 
with previous reports (Bhawal et al., 2011; Qian et al., 2008), Stra13 over-
expressing cells resulted in reduced cell numbers compared to vector 
expressing cells, whereas Stra13 2KR expressing cells proliferated similar to 
control cells (Figure. 3.3.1A).  
To further confirm the finding that sumoylation plays a role in Stra13-
mediated growth arrest, mouse embryonic fibroblast (MEFs) cells derived 
from Stra13-/- mice were transfected with Stra13 and Stra13 2KR as well as 
vector control and MTT assay was performed to examine the cell viability. 
Consistently, re-expression of wild type Stra13 but not Stra13 2KR in MEF 
cells led to growth suppression (Figure 3.3.1 B). These observations strongly 
suggest that sumoylation is involved in the inhibition of cell proliferation 
mediated by Stra13. 
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Figure 3.3.1 Sumoylation is required for Stra13-mediated 
inhibition of proliferation. (A) NIH3T3 cells were cotransfected with 
Myc-Stra13 or Stra13 2KR together with a puromycin resistance 
plasmid. After selection, growth of cells expressing vector alone, Stra13 
and Stra13 2KR was evaluated over a five-day period. Cell numbers at 
each time point are represented as mean±SD. (B) Stra13-/-   MEFs were 
transfected at passage 5 with equivalent amounts of Stra13 and Stra13 
2KR. Cell viability was measured three days later by MTT assays. 
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3.3.2 Sumoylation interfers with the ability of Stra13 to induce G1 
arrest  
Increasing evidence demonstrate that over-expression of Stra13 is able to 
affect cell cycle progression by arresting cell cycle at G1 phase, therefore 
suppress cell growth  (Qian et al., 2008; Bhawal et al., 2011). To investigate 
whether the effect of sumoylation on Stra13-mediated growth suppression is 
related to cell cycle arrest, we examined the cell cycle profile of Stra13 and 
Stra13 2KR along with control vector expressing cells by flow cytometry. All 
these three types of cells were seeded at 1x106 cells/10-cm plate. 24 hours 
later, cells were fixed with cold 70% ethanol and stained with PI. The PI-
stained cells were analyzed by flow cytomety (Becton Dickinson). Over-
expression of Stra13 consistently delayed progression in the G1/S phase of the 
cell cycle, resulting in G1 arrest. In contrast, the cell cycle profile of Stra13 
2KR cells was similar to that of control cells (Figure 3.3.2). However, 
expression of either protein had no impact on the sub-G1 phase. These results 
suggest that sumoylation of Stra13 affects the ability of Stra13 to induce G1 






















3.4   Mechanism underlying SUMO modification of Stra13 in cell cycle 
arrest 
3.4.1 Sumoylation of Stra13 is required to inhibit endogenous cyclinD1  
It has been well established that cyclinD1 is a key regulator of the cell cycle 
and plays an important role during the transition of cell cycle from G1 to the S 
phase by binding and activating specific types of cyclin-dependent kinases 
(CDKs), and the down-regulation of cyclinD1 will lead to G1 arrest of cell 
cycle (Weinberg, 1995; Harbour and Dean, 2000). A recent study showed that 
Stra13 negatively regulated cyclinD1 and inhibited the expression level of 
cyclinD1, and this repression was physiologically relevant to the diminished 
Figure 3.3.2 Sumoylation interfers with the ability of Stra13 to 
induce G1 arrest Selected NIH3T3 cells expressing Stra13 or Stra13 2KR 
as well as empty vector were seeded at a density of 1x106 cells per 10-cm 
plate. Cell cycle profile of control vector, Stra13 and Stra13 2KR cells was 
determined by PI staining and FACS analysis. Representative histograms 
of cell cycle profiles in cells expressing vector alone, Stra13 and Stra13 
2KR. The result shown is representative of three independent experiments. 
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cell proliferation and invasion rate exhibited by overexpression of Stra13 
(Bhawal et al., 2011). To determine the molecular basis underlying Stra13-
mediated G1 arrest, we therefore examined whether the influence of Stra13 
sumoylation on growth inhibition, proliferation suppression and cell cycle 
arrest was associated with the repression on the level of endogenous cyclinD1 
together with p21 which is also involved in regulating G1/S transition. To test 
this possibility, stable NIH3T3 cells expressing empty vector or Myc-tagged 
Stra13, Stra13 2KR mutant were synchronized in mitosis with nocodazole at 
final concentration of 500 ng/ml for 16 hours, and then released into G1 phase 
by washout. 24 hours later, cells were re-plated and grown in 10 cm dishes for 
two days. Total RNA was isolated and real time reverse transcriptase-PCR (Q-
PCR) was performed for cyclinD1, p21, cyclinB1 and cyclinE1 together with 
GAPDH. Consistent with published data (Bhawal et al., 2011), Stra13 
significantly inhibited endogenous cyclin D1 expression, and up-regulated the 
levels of p21. In contrast, Stra13 2KR expressing cells did not show a 
significant change in either cyclinD1 or p21 expression (Figure 3.4.1A). 
Cyclin B1 and cyclin E1 expression was similarly regulated in cells expressing 
Stra13 and Stra13 2KR (Figure 3.4.1B). To validate these findings, protein 
levels of cyclin D1 and p21 were examined by western blotting with anti-
cyclinD1 and anti-p21 antibodies. Consistently, Stra13 WT was more effective 
at repression of cyclinD1 level than Stra13 2KR mutant (Figure 3.4.1C). These 





                     
           








Figure 3.4.1 Sumoylation is required to inhibit endogenous 
cyclinD1   (A, B) NIH3T3 cells expressing control vector, Stra13 and 
Stra13 2KR were synchronized in mitosis by nocodazole at final 
concentration of 500 ng/ml. At 16 hours after release from mitosis by 
washout, cells were replated. 24 hours later, total RNA was isolated. 
mRNA levels of cyclinD1, p21Cip/WAF, cyclin B1 and cyclin E1 were 
analyzed by Q-PCR in vector, Stra13 and Stra13 2KR cells. (C) Lysates 
were collected from the nocodazole-treated cells and immunoblotted 
with anti-cyclin D1, p21 and β-actin antibody by western blotting. 
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3.4.2 Sumoylated Stra13 represses cyclinD1 promoter  
Since sumoylation typically enhances transcriptional repression, and Stra13 is 
a transcriptional repressor of cyclin D1, we examined whether sumoylation is 
required for Stra13-mediated repression of cyclinD1 promoter activity. A 
cyclinD1 promoter reporter (Hinz et al., 1999) was co-expressed with Stra13 
and SUMO1. Consistent with the repression of endogenous cyclinD1 
expression, Stra13 significantly repressed the cyclinD1 promoter luciferase 
reporter activity, which was further augmented in presence of SUMO1. The 
2KR mutant was much less effective than WT Stra13 in repression of the 
cyclin D1 promoter reporter (Figure 3.4.2). To further confirm that the effect 
of Stra13 2KR on repression of cyclinD1 promoter was a result of a lack of 
SUMO1 modification, the SUMO protease SENP1 was added. In the presence 
of SENP1, the ability of Stra13 to repress the expression of cyclinD1 reporter 
was attenuated significantly (Figure 3.4.2), confirming that sumoylation is 














3.5 Molecular mechanism underlying SUMO-dependent cyclin D1 
repression by Stra13 
3.5.1 SUMO modification of Stra13 does not affect its sub-cellular 
localization  
Sumoylation has been shown to affect the subcellular localization of a lot of 
target proteins such as promyelocytic leukemia protein (PML), MEK1, and 
Sp3 (Muller et al., 1998; Ross et al., 2002). One of the mechanisms for 
SUMO related transcriptional repression can be executed by altered cellular 
localization (Gill, 2003). To determine whether the inability of Stra13 2KR to 
repress cyclin D1 was due to the altered cellular localization, we examine the 
cellular distribution of sumoylated Stra13 and SUMO-defective Stra13 
mutants. COS 7 cells were transfected with Myc-tagged wild type Stra13 or 
Figure 3.4.2 Sumoylated Stra13 is a strong specific 
transcriptional repressor of cyclinD1 promoter. (A) NIH3T3 cells in 
a 24-well dish were co-transfected with cyclin D1 promoter reporter 
pD1Luc (100 ng) together with Stra13 (25 ng), Stra13 2KR (25 ng), 
SUMO1 (25 ng) or SENP1 (25 ng), as indicated. Cells were harvested 
48 hours after transfection, and assayed for luciferase activity. Error 
bars represent mean±SD.  
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mutants. 48 hours later, cells were fixed and analyzed by immunostaining. 
Myc-tagged Stra13 was probed with anti-Myc antibody, and then stained with 
Texas-red conjugated second antibody. Nuclei were stained with DAPI. 
Confocal microscopy showed that both Stra13 WT and its mutants yielded 
nearly identical patterns of nuclear localization, independent of sumoylation 
status (Figure 3.5.1 upper panel). Similarly, no apparent differences in sub-
nuclear localization were observed between wild type and Stra13 sumoylation 
mutants under basal condition with the addition of SUMO1 (Figure 3.5.1 
bottom panel ). These observations suggest that sumoylation of Stra13 is not 










Figure 3.5.1 Sumoylation does not affect sub-cellular localization 
of Stra13. COS7 cells were transfected with 1 ug of Stra13 and Stra13 
2KR alone or together with 1 ug of SUMO1. 48 hours later, cells were 
stained with anti-Myc antibody. Nuclei were stained with DAPI.  
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3.5.2 CyclinD1 is directly regulated by Stra13 
Stra13 is able to negatively regulate expression of cyclinD1 (Bhawal et al., 
2011), and our results suggest that the effect of sumoylation of cyclinD1 
repression by Stra13 is not due to altered subcellular localization (Figure 
3.5.1). These data led us to ask whether cyclin D1 is directly negatively 
regulated by Stra13. To examine this possibility, we performed Chromatin 
Immunoprecipitation (ChIP) assays in NIH3T3 where the endogenous Stra13 
was stimulated by the treatment of trichostatin A (TSA) which has been shown 
to be able to cause growth arrest in fibroblast cells (Sun and Taneja, 2000). As 
shown in Figure 3.5.2, binding of endogenous Stra13 was evident on the 
cyclinD1 promoter both in the absence and presence of TSA treatment (Figure 
3.5.2). This observation indicates that cyclinD1 is a Stra13 target gene.                   








Figure 3.5.2 CyclinD1 is a direct target of Stra13. NIH3T3 cells were 
left untreated or treated with TSA at a final concentration of 1 uM. 24 
hours later,  ChIP assays were carried out to determine Stra13 occupancy 
on the cyclinD1 promoter. Lysates were pulled down with anti-Stra13 
antibody and the binding of Stra13 WT and mutant to cyclin D1 promoter 
was examined by real-time PCR.
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3.5.3 Sumoylation alters the interaction between HDAC1 and Stra13 
Sumoylation has been show to alter the protein-protein interactions (Gill, 
2003; Erica, 2004). Our lab has previously demonstrated that the co-repressor 
HDAC1 interacts with the C-terminal region of Stra13 spanning amino acid 
residues111-343, which is responsible for its repression activity (Sun and 
Taneja, 2000). As Stra13 sumoylation sites K159 and K279 are located within 
the HDAC1 interaction region (Figure 3.1.1), we therefore investigated 
whether the association between HDAC1 and Stra13 is sumoylation 
dependent. HEK293 cells were transfected with Myc-tagged Stra13 or Stra13 
2KR mutant together with Flag-tagged HDAC1. Lysates were 
immunoprecipitated with Myc-c-agarose beads followed by western blotting 
with anti-Flag antibody (Figure 3.5.3.A). Consistent with previous report (Sun 
and Taneja, 2000), wild type Stra13 strongly interacted with HDAC1, whereas 
sumoylation-defective mutant Stra13 2KR interacted less efficiently with 
HDAC1, indicating that sumoylation is involved in the protein-protein 














3.5.4 Sumoylation is required for endogenous Stra13 to interact  with  
HDAC1 
To validate this finding that sumoylation affect the interaction between 
HDAC1 and Stra13, we examined whether the association between 
endogenous Stra13 and HDAC1 is also regulated by sumoylation. Endogenous 
Stra13 was immunoprecipitated from cells in the absence or presence of TSA 
treatment. Consistent with the enhanced endogenous Stra13 sumoylation in 
TSA treated cells (Figure 3.2.3), the association between endogenous Stra13 
and HDAC1 is also enhanced in the presence of TSA (Figure 3.5.4 A). To 
further confirm that only SUMO-conjugated Stra13 can interact effectively 
with HDAC1, we examined the interaction between endogenous HDAC1 and 
Stra13 in cell lines such as MCF7 and K562 cells. Both Stra13 and HDAC1 
Figure 3.5.3 Sumoylation affects the interaction between 
HDAC1 and Stra13. NIH3T3 cells were co-transfected with 
plasmids expressing Flag-HDAC1 and Myc-Stra13 or Stra13 2KR. 48 
hours after transfection, lysates were immunoprecipitated with Myc 
agarose beads and analyzed for interaction by western blotting with 
anti-Flag antibody anti-Stra13 antibody and immunoblotted with anti-
SUMO1 and anti-HDAC1 antibodies. 
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were expressed in K562 cells (Figure 3.5.4 B). Lysates with or without the 
SUMO protease inhibitor NEM were immunoprecipitated with anti-Stra13 
antibody and detected with anti-SUMO1 and anti-HDAC1 antibodies. Only in 
NEM treated samples, the endogenous Stra13 interacted with endogenous 
HDAC1 (Figure 3.5.4 B). Similar results were obtained in MCF7 cells (Figure 
3.5.4 C), suggesting that the interaction between endogenous Stra13 and 
HDAC1 is related to SUMO conjugation. Taken together, these data strongly 
indicate that the association between HDAC1 and Stra13 is SUMO-dependent.    
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3.6    HDAC1 can negatively regulate the sumoylation of Stra13 
3.6.1 Over-expression of HDAC1 represses sumoylation of Stra13  
Several studies have demonstrated that HDACs are able to modulate 
sumoylation of the target proteins (Gregoire et al., 2005; Stankovic-Valentin 
et al., 2007). These observations led us to ask whether HDAC1 regulates 
Stra13 sumoylation. To address this question, cells were co-transfected with 
Myc-Stra13 and Stra13 2KR along with SUMO1 and Flag-HDAC1. Lysates 
were subjected to immunoprecipitation with Myc-c-agarose beads followed by 
western blotting with anti-SUMO1 antibody. Interestingly, Stra13 sumoylation 
Figure 3.5.4 Sumoylation is required for endogenous Stra13 to 
interact  with  HDAC1 (A) NIH3T3 cells were left untreated (-) or 
treated (+) with TSA at a final concentration of 1 uM. 24 hours 
later, endogenous Stra13 was immunoprecipitated and analyzed for 
association with HDAC1. (B) Cell lysates of K562 cells, extracted 
in the absence (-) or presence (+) of 20mM N-ethylmaleimide 
(NEM) were immunoprecipitated (IP) with anti-Stra13 antibody and 
immunoblotted with anti-SUMO1 and anti-HDAC1 antibodies. (C) 
Cell lysates of MCF7 cells, extracted in the absence (-) or presence 
(+) of 20mM N-ethylmaleimide (NEM) were immunoprecipitated 
(IP) with anti-Stra13 antibody and immunoblotted with anti-
SUMO1 and anti-HDAC1 antibodies. 
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was almost abolished with the addition of HDAC1 (Figure 3.6.1 A). To 
confirm this effect of HDAC1, TSA, a specific histone deacetylase inhibitor 
which can inhibit the activity of HDAC1 was added. Cells were transfected 
with Myc-Stra13 and Stra13 2KR together with Flag-HDAC1. Western 
blotting with anti-SUMO1 antibody clearly revealed that TSA dramatically 
increased sumoylation of Stra13 reduced by HDAC1 (Figure 3.6.1 B). These 




                                         
          
                       












3.6.2 Down-regulation of HDAC1 enhances Stra13 sumoylation  
To further validate the effect of HDAC1 on Stra13 sumoylation, endogenous 
HDAC1 was down-regulated with siRNA (siHDAC1) in NIH3T3 cells. Cells 
were transfected with siHDAC1 or scrambled siRNA as a control. Myc-Stra13 
and SUMO1 were transfected into siHDAC1 and siRNA cells. 24 hours post-
transfection, lysates were collected and subjected to immunoprecipitation with 
Myc-c-agarose followed by western blotting with anti-SUMO1 antibody. The 
down-regulation of HDAC1 levels was apparent by western blotting with anti-
HDAC1 antibody (Figure 3.6.2 A). Down-regulation of HDAC1 expression in 
siHDAC1 cells led to enhanced Stra13 sumoylation compared to controls 
(Figure 3.6.2 B), demonstrating that HDAC1 can regulate Stra13 sumoylation 
endogenously. 
Taken together, our results strongly indicate that sumoylation of Stra13 is 
modulated by HDAC1. 
 
Figure 3.6.1 HDAC1 negatively regulates sumoylation of Stra13. (A) 
NIH3T3 cells were co-transfected with constructs encoding Myc-Stra13, 
Flag-HDAC1 and SUMO1. 48 hours after transfection, cells were 
immunoprecipitated with Myc-agarose beads followed by western blotting 
with anti-SUMO1 antibody. (B) Same transfection as (A) was performed. 
24 hours later, TSA was added at a final concentration of 300 nM. After 24 
hours, cell lysates were immunoprecipitated with Myc agarose beads 
followed by western blotting with anti-SUMO1 antibody.  
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3.7    HDAC1 affects Stra13-mediated growth arrest 
3.7.1  HDAC1 inhibits the growth suppression mediated by Stra13 
In contrast to the anti-proliferative effect of Stra13, HDAC1 has been shown 
to promote proliferation via regulation of G1/S progression (Teppei et al., 
 
 
Figure 3.6.2 Down-regulation of endogenous HDAC1 
enhances sumoylation of Stra13. (A) NIH3T3 cells were 
knocked down of HDAC1 with siRNA of HDAC1 at a final 
concentration of 100 nM. 24 hours after transfection, Myc-Stra13 
and SUMO1 were transfected into siHDAC1 cells. Endogenous 
HDAC1 expression in siHDAC1 cells compared to control cells 
was examined by western blotting. (B) Lysates were 




2010; Hideki et al., 2003). Since our data suggest that HDAC1 can regulate 
sumoylation of Stra13, and Stra13-mediated growth arrest is sumoylation-
dependent, we examined whether HDAC1 antagonizes SUMO-dependent 
Stra13-mediated growth suppression. NIH3T3 cells were co-transfected with 
equivalent expression levels of Myc-Stra13 and Myc-Stra13 2KR along with 
Flag-HDAC1 in the presence of puromycin resistance gene pD503. The 
expression for the proteins indicated was examined by western blotting with 
anti-Myc and Flag antibodies (Figure 3.7.1.A). After selection with puromycin 
for 3 days, cells were seeded at a low density and colony formation assays 
were performed. Interestingly, in the presence of HDAC1, Stra13-mediated 
growth suppression was abrogated, which phenotypically resembled Stra13 
2KR cells (Figure 3.7.1.B & C). This result suggests that HDAC1 inhibits the 
growth suppression mediated by Stra13. 
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3.7.2  HDAC1 abrogates  Stra13-mediated repression on cyclin D1 
We have shown that sumoylated Stra13 is a transcriptional repressor of 
cyclinD1 (Figure 3.4.2). Therefore, we asked whether the loss of Stra13-
mediated growth suppression by HDAC1 occurs due to de-repression of the 
cyclinD1 promoter. To test this possibility, the cyclinD1 reporters with 
different doses were co-expressed with Stra13 WT and SUMO1, and then 
luciferase reporter assays were performed. Consistent with the inhibition of 
HDAC1 on Stra13-mediated growth suppression, repression of the cyclinD1 
promoter by Stra13 and SUMO1 was attenuated in a dose-dependent manner 
when HDAC1 was added (Figure 3.7.2.A). To validate the effect of HDAC1 
in Stra13-mediated transcriptional repression on cyclin D1 promoter, 
endogenous HDAC1 was knocked down with siHDAC1. In contrast with the 
inhibition of over-expressed HDAC1, Stra13-mediated repression of cyclinD1 
Figure 3.7.1 HDAC1 inhibits the growth suppression mediated by 
Stra13. (A) NIH3T3 cells were co-transfected with Myc-Stra13 or Stra13 
2KR and Flag-HDAC1. Lysates were subjected to western blotting with 
anti-Myc and anti-Flag antibodies to detect expression of Stra13 and 
HDAC1. (B) Colony assays were performed, and representative plates 
stained with crystal violet are shown. (C) Colony assays were quantified by 
measuring the absorbance of extracted crystal violet dye at 570 nm.  
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promoter reporter was augmented in siHDAC1 cells compared to control 
siRNA knock down cells (Figure 3.7.2.B). These results demonstrate that the 
loss of growth inhibition by HDAC1 is due to its ability to suppress the 
repression of cyclinD1 reporter by Stra13. 
 
          
 








Figure 3.7.2 HDAC1 abrogates Stra13-mediated repression of 
cyclin D1. (A) NIH3T3 cells were co-transfected with pD1luc reporter 
(100 ng) with Myc-Stra13 (25 ng) and SUMO (25 ng) in the presence of 
increasing amounts of HDAC1 (25, 50 and 100 ng). 48 hours later, 
luciferase activity was assayed. (B) siHDAC1 cells and controls were 
transfected with  pD1luc reporter (100 ng) in the absence and presence of 
Stra13(25 ng). Luciferase activity was measured 24 hours later. Error bars 
indicate mean± SD. 
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3.8   Sumoylation is involved in Stra13-mediated cellular senescence  
Recent studies have shown that over-expression of Stra13 induces senescence 
(Xu et al., 2012; Qian et al., 2008), and Stra13 is a downstream target of p53 
in cellular senescence (Qian et al., 2008). The SUMO pathway has recently 
been implicated in the process of cellular senescence (Bischof et al., 2006), 
and a number of senescence-associated proteins such as p53 and RB were 
identified to be the targets for SUMO conjugation (Muller et al., 2000). These 
established data led us to ask whether sumoylation could influence Stra13-
mediated senescence. To address this question, we performed SA-β-
Galactosidase staining assay.  
3.8.1   Sumoylation can affect cellular senescence induced by Stra13 
To test the possibility that sumoylation is involved in the regulation of the 
cellular senescence mediated by Stra13, cells expressing Stra13 or Stra13 2KR 
were seeded at low density in 6-well plates. After 7-10 days, SA-β-
Galactosidase staining assay was performed to compare the number of the 
senescence cells or SA-β-Galactosidase-positive cells which usually exhibit 
enlarged cell size, flattened morphology and blue perinuclear staining between 
Stra13 and Stra13 2KR cells. To quantify the extent of senescence, around 
1000 cells were counted and the cells stained blue were defined as positive 
senescent colonies. Western blotting analysis with anti-Myc antibody showed 
equivalent expression of Stra13 and Stra13 2KR (Figure 3.8.1 A). Consistent 
with previous reports (Qian et al., 2008; Xu et al., 2012), over-expression of 
Stra13 resulted in significant increase in the percentage of SA-β-
Galactosidase-positive colonies compared with that in vector-transfected cells 
(Figure 3.8.1 B, C). Interestingly, in contrast to wild type Stra13, Stra13 2KR 
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was unable to promote cellular senescence significantly (Figure 3.8.1 B, C). 
This strongly indicates that sumoylation plays an important role in regulating 
Stra13- induced cellular senescence. 
 
 
       
 


















3.8.2 Sumoylation is essential for Stra13-dependent cellular senescence  
The inability of Stra13 2KR mutant to enhance cellular senescence suggested 
that sumoylation may be involved in the effect of Stra13 on cellular 
senescence. To further determine the impact of sumoylation on Stra13-induced 
cellular senescence, we asked whether suppression of sumoylation on Stra13 
by SENP which removes SUMO from target proteins can recapitulate the 
phenotype of the cells expressing Stra13 2KR mutant. To test this possibility, 
we co-expressed SENP1 along with equivalent expression levels of Stra13 and 
Stra13 2KR in NIH3T3 cells (Figure 3.8.2A), and then performed SA-β-
Galactosidase staining assay at day 7 post selection. Interestingly, co-
expression of SENP1 reversed the increased in number of senescent cells 
induced by Stra13, and resembled Stra13 2KR expressing cells. As expected, 
Stra13 2KR was not as sensitive to SENP1 as Stra13 WT (Figure 3.8.2 B, C), 
confirming that sumoylation is indeed playing an important role in regulating 
cellular senescence mediated by Stra13. 
 
Figure 3.8.1 Sumoylation can affect cellular senescence induced by 
Stra13.   (A) NIH3T3 cells were co-transfected Stra13 or Stra13 2KR 
together with a puromycin resistance plasmid. Empty vector (pCS2) was 
transfected in control cells (vector). Stra13 expression was determined by 
western blotting using anti-Myc antibody. (B-C) SA-β-Galactosidase 
staining assays were performed with control, Stra13 and Stra13 2KR cells 
at day 7 postselection. Representative photomicrographs are shown (B). 
Quantitation of data in (B), showing the percentage of SA-β-
Galactosidase staining positive cells. The error bars indicate standard 













Figure 3.8.2 Sumoylation is essential for Stra13-induced cellular 
senescence. (A) NIH3T3 cells were co-transfected Stra13 or Stra13 
2KR together with a puromycin resistance plasmid. Empty vector 
(pCS2) was transfected in control cells (vector). Stra13 expression was 
determined by western blotting using anti-Myc antibody. (B-C) After 
selection, SA-β-Galactosidase staining assays were performed in 
control, Stra13 and Stra13 2KR cells at day 7 after seeding. 
Representative photomicrographs are shown (B). The percentage of 
SA-β-Galactosidase staining positive cells was calculated for 
quantitation in (B). The error bars indicate standard deviations for 
triplicate experiments (C). 
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3.8.3 Sumoylation regulates Stra13-mediated cellular senescence 
through p53/p21 pathway 
Senescence signals are transduced mainly through p53/p21 and Rb/p16 
pathways (Ben-Porath et al., 2005; Campisi et al., 2007). Previous studies 
demonstrated that   p53/p21 pathway plays a key role in Stra13-induced 
cellular senescence (Qian et al., 2008; Xu et al., 2012). To characterize the 
mechanism underlying SUMO-dependent senescence induced by Stra13, we 
examined the expression level of these regulatory proteins. NIH3T3 cells 
expressing equal levels of Stra13 or Stra13 2KR together with control vector 
were seeded at 1x106 cells/10-cm plate, lysates were collected at day 1 and 
day 7 post-selection for western blotting analysis with different antibodies. 
Consistent with the previous reports (Qian et al., 2008), we reproducibly 
found that over-expression of Stra13 was able to induce a modest 
accumulation of p53 at 24 hours post-transfection as well as d1 after selection 
(Figure 3.8.3 A, B). Conversely, the expression of p53 was not enhanced in 
the Stra13 2KR cells compared to vector controls. p21 was identified as an 
over-expressed gene in senescent cells, and it has been shown that p21 is 
capable of inducing premature senescence even in p53-null cells (Wang et al., 
1999). To determine whether p21 plays a role in SUMO-mediated cellular 
senescence induced by Stra13, the endogenous p21 levels were also examined. 
We found that p21 was up-regulated in Stra13 expressing cells at different 
time points, whereas, it was not significantly affected in Stra13 2KR 
expressing cells which shows almost the same expression level as control cells 
(Figure 3.8.3 A, B, C). We also examined the Rb levels in cells expressing 
Stra13 WT and 2KR, and no apparent difference in Rb expression was found 
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in both cells. These findings further confirm that Stra13 can activate p53/p21 
pathway to induce cellular senescence and this activation is SUMO-dependent. 
 
                      
 
 
                      
  














3.9 HDAC1 is not involved in regulation of the cellular senescence 
induced by Stra13 
Emerging evidence shows that HDAC1 plays critical roles in not only in 
proliferating cells but also in senescent cells in culture as well as in young and 
old tissues in vivo (Lagger et al., 2002; Bandyopadhyay et al., 2007). Recent 
work by Chuang et al indicates that HDAC1 has the ability to induce cellular 
senescence through deacetylation of Sp1 and PP2A pathway (Chuang et al., 
2011). Our current work suggests that HDAC1 inhibits Stra13 sumoylation 
(Figure 3.6.1A), and consequently its ability to repress cyclin D1 which is 
essential for growth suppression (Figure 3.7.2A). These observations and 
findings led us to ask whether HDAC1 is also able to regulate Stra13-induced 
cellular senescence that is sumoylation-dependent. To test this possibility, 
NIH3T3 cells were co-transfected with Myc-tagged Stra13 and Flag-tagged 
HDAC1 (Figure 3.9.1). Consistently, over-expression of Stra13 induced 
senescence, while surprisingly, the addition of HDAC1 could not inhibit cell 
Figure 3.8.3 Sumoylation regulates Stra13-mediated cellular 
senescence through p53/p21 pathway. (A) NIH3T3 cells were co-
transfected with Stra13 or Stra13 2KR together with a puromycin resistance 
plasmid. Empty vector (pCS2) was transfected in control cells (vector). 24 
hours later, half of cells were harvested for lysates. Western blotting was 
conducted with different antibodies: anti-Myc antibody for expression level 
of Stra13 and Stra13 2KR; anti-p53 and anti-p21 antibodies were used for 
detecting endogenous p53 and p21. (B-C) 24 hours after transfection, half of 
the cells were selected in the presence of 1.2 ug/ml puromycine for 3 days. 
Cell lyastes were collected at day 1 and day7 for western blotting with 
antibodies indicated.   
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senescence to the level in Stra13 2KR cells as expected (Figure 3.9.1). This 























To further investigate whether the cellular senescence induced by Stra13 can 
be regulated by HDAC1, we knocked down endogenous HDAC1 by using 
siRNA. Myc-Stra13 was transfected into both siHDAC1 and siRNA control 
cells together with puromycin resistance plasmid pBABE. After selection with 
puromycin for 3 days, cells were seeded at low density in 6-well plates. 7 days 
later, SA-β-Galactosidase staining assays were performed. Down-regulation of 
HDAC1 expression did not affect the cellular senescence induced by Stra13 
(Figure 3.9.2). Taken together, these results indicate that the cellular 
senescence induced by Stra13 is not mediated by HDAC1. 
 
 
    
Figure 3.9.1 Over-expression of HDAC1 does not affect Stra13-
mediated cellular senescence (A) NIH3T3 cells were co-transfected with 
Stra13 or HDAC1 together with a puromycin resistance plasmid. Empty 
vector (pCS2) was transfected in control cells (vector). 24 hours later, the 
cells were selected in the presence of 1.2 ug/ml puromycine for 3 days. (B-
C) SA-β-Galactosidase staining assays were performed in control, Stra13 
and Stra13 2KR cells at day 7 after seeding. Representative 
photomicrographs are shown (B). The percentage of SA-β-Galactosidase 
staining positive cells was calculated for quantitation. The error bars 
indicate standard deviations for triplicate experiments (C). 
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Figure 3.9.2 Down-regulation of HDAC1 does not affect the cellular 
senescence induced by Stra13 (A) NIH3T3 cells were transfected 
siHDAC1 and scrambled siRNA as a control. 24 hours later, Myc-Stra13 
was transfected into both of the cells together with a puromycin resistance 
plasmid. Knockdown of endogenous HDAC1 and over-expression of Stra13 
was detected by western blotting with anti-HDAC1 and anti-Stra13 
antibodies. (B) After selection, SA-β-Galactosidase staining assays were 
performed in cells at day 7 after seeding. Representative photomicrographs 
are shown (C). The percentage of SA-β-Galactosidase staining positive cells 
was calculated for quantification. The error bars indicate standard deviations 









SUMOYLATION IN REGULATION OF 














4.1   Sharp-1 is SUMO conjugated 
4.1.1  Sharp-1 contains two SUMO motifs 
Sharp-1 has been demonstrated to inhibit skeletal muscle cell differentiation 
through transcriptional repression of MyoD activity (Amzi et al., 2004).  
Moreover, we have recently reported that Sharp-1 associateed with the co-
repressor G9a to inhibit differentiation of skeletal muscle precursor cells (Ling 
et al, 2012a). However the mechanisms by which the association of Sharp-1 
with G9a is modulated are unclear. The region of interaction with G9a mapped 
to amino acid residues 173-265 in Sharp-1. Upon inspection of the Sharp-1 
cDNA sequence for potential sumoylation sites in this region, two highly 
conserved lysine residues that perfectly matched the consensus sumoylation 
motif were identified: lysine (K) 240 in the sumoylation motif VKQE; and 










Figure 4.1.1 Sharp-1 contains two SUMO motifs (A) The domain 
structure Sharp-1 is shown with the basic DNA-binding domain, helix-loop-
helix (HLH) dimerization domain, and the Orange domain involved in 
transcriptional repression (upper panel). Potential sumoylation sites at K240 
and K255 are indicated. Alignment of the two SUMO consensus motifs in 
Sharp-1 cDNA from human, mouse, rat, dog and xenopus showed high 
conservation across species. 
 
4.1.2  Sharp-1 is sumoylated 
To determine whether Sharp1 undergoes sumoylation, we transiently co-
transfected HEK293 cells with Myc-Sharp1 and SUMO1. Cells were lysed in 
the presence of N-ethylmaleimide and lysates were immunoprecipitated with 
Myc-c-agarose beads followed by western blotting with anti-SUMO1 
antibody. In the presence of SUMO1, an additional higher molecular weight 
band was detected (Figure 4.1.2). To confirm that this represented putative 
sumoylated Sharp-1, we co-transfected SENP1, which is able to remove 
SUMO conjugates from target proteins. Sumoylation was almost abolished in 








      
  
 
Figure 4.1.2 Sharp-1 is sumoylated   H293 cells were co-transfected with 
constructs encoding Myc-Sharp-1, SUMO1 and SENP1 as indicated. Lysates 
were subjected to immunoprecipitation with Myc-c-agarose beads followed by 
immunoblotting with anti-SUMO1 antibody. Anti-Myc antibody was used to 
detect expression of Sharp-1. β-actin served as a loading control. 
 
4.1.3 Lys 240 is primary site for sumoylation  
To identify that K240 and K255 are indeed sumoylation sites, we generated 
point mutants by changing the putative target lysine residues to arginine with 
site-directed mutagenesis. These mutants as well as wild type Sharp-1 were 
co-expressed with SUMO1 in cells. Immunoprecipitation and western blotting 
analysis revealed that mutation of K240 alone (K240R), or both K240 and 
K255 (2KR) to arginine abrogated sumoylation even in the presence of 






         
 
Figure 4.1.3 Lys 240 is primary site for sumoylation  Cells were co-
transfected with Myc-Sharp-1, Sharp-1 K240R, and Sharp-1 2KR along with 
SUMO1. Lysates were immunoprecipitated with Myc-agarose beads followed 
by western blotting with anti-SUMO1 antibody. 
 
 
4.1.4 PIAS3 and PIASxa E3 SUMO ligases enhance Sharp-1 umoylation 
To determine whether PIAS proteins regulate Sharp-1 sumoylation, we co-
transfected cells with Myc-Sharp-1, SUMO1 and Flag-PIAS1, PIAS3, 
PIASxα, and PIASy. Cell lysates were immunoprecipitated with Myc-agarose 
beads, followed by western blotting with anti-SUMO1 antibody. PIASs 
proteins were equally expressed. Overexpression of PIAS3 and PIASxα 
enhanced sumoylation of Sharp-1, whereas the presence of PIAS1 and PIASy 
had a minimal impact, suggesting that PIAS3 and PIASxα act as E3 SUMO 





     
 
Figure 4.1.4 PIAS3 and PIASxa E3 SUMO ligases enhanced Sharp-1 
sumoylation. Flag-tagged PIAS1, PIAS3, PIASxa and PIASy were co-
transfected with Myc-Sharp-1 and SUMO1. Cell lysates were 
immunoprecipitated with Myc-c-agarose beads and immunoprecipitates were 
subjected to western blotting with anti-SUMO1 antibody. Sharp-1 and PIAS 
proteins were detected with anti-Myc and anti-Flag antibodies respectively. 
 
 
4.1.5 Endogenous Sharp-1 is sumoylated 
To examine whether sumoylation of Sharp-1 is physiologically relevant in 
myogenesis, we first determined whether Sharp-1 is SUMO conjugated in 
skeletal muscle cells. C2C12 cells were co-transfected with Myc-Sharp1 and 
SUMO1. Cell lysates from undifferentiated cells (D0) and 24 hours after 
induction of differentiation (D1) were immunoprecipitated with Myc-agarose 
beads followed by western blotting with anti-SUMO1 antibody. Sumoylation 
of Sharp-1 was detected in C2C12 cells at D0, and was significantly reduced 
upon differentiation (Figure 4.1.5 A). To further validate this finding, 
endogenous Sharp-1 was immunoprecipitated from C2C12 cells in the 
conditions of undifferentiation (D0) and differentiation (D1). Similarly, 
endogenous Sharp-1 was also SUMO conjugated in undifferentiated C2C12 
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cells (D0) and this conjugation was reduced when cells were induced to 










4.2   Sub-cellular localization of Sharp-1 is not altered upon sumoylation  
To determine whether sumoylation alters sub-cellular distribution, we 
analyzed localization of Sharp-1 and Sharp-1 2KR in COS-7 cells. Cells were 
transfected with Myc-Sharp1 or Sharp-1 2KR in the absence or presence of 
 
Figure 4.1.5 Endogenous Sharp-1 is sumoylated (A) C2C12 cells 
were co-transfected with Myc-Sharp-1 and SUMO1. 24 hours later, cells 
were re-seeded for differentiation. Cells were harvested at D0 and D1, 
and then immunoprecipitated with Myc-agarose beads followed by 
western blotting with anti-SUMO1 antibody. (B) C2C12 cells were 
transfected with SUMO1. Endogenous Sharp-1 was extracted from cells 
at D0 and D1, and lysates were immunoprecipitated with anti-Sharp-1 
antibody followed by western blotting with anti-SUMO1 antibody. 
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SUMO1, immunostained with anti-Myc antibody and visualized by confocal 
microscopy. Both proteins showed almost identical patterns of localization 
(Figure 4.2), suggesting that the nuclear localization of Sharp-1 is independent 
of its sumoylation status.  
 









Figure 4.2. Sub-cellular localization of Sharp-1 is not altered upon 
sumoylation. COS-7 cells were transfected with Sharp-1 and Sharp-1 
2KR alone or together with SUMO1. 48 hours later, cells were fixed and 




 4.3  Sumoylation of Sharp-1 is essential to inhibit myogenic 
differentiation  
4.3.1 Sharp-1 sumoylation modulates its ability to suppress myogenesis  
Sharp-1 inhibits the differentiation of skeletal muscle precursor cells (Azmi et 
al., 2004; Ling et al., 2012a). Since our results demonstrated that endogenous 
Sharp-1 was SUMO conjugated in undifferentiated C2C12 cells and this 
conjugation is reduced upon differentiation (Figure 4.1.5). We examined 
whether sumoylation is involved in Sharp-1 mediated inhibition of skeletal 
muscle cell differentiation. To test this possibility, C2C12 cells were co-
transfected with Myc-tagged Sharp-1, Sharp-1 2KR together with the 
puromycin resistance vector pBabe and induced to differentiate. Both Myc-
Sharp-1 and Myc-Sharp-1 2KR were expressed at similar levels (Figure 4.3.1 
A). After 2 days in differentiation medium, cells were fixed and stained for 
MHC, a late marker of differentiation predominantly expressed in myotubes. 
Consistent with our previous report (Azmi et al., 2004), overexpression of 
Sharp-1 resulted in significant inhibition in myogenic differentiation as 
evidenced by reduced myogenic index compared with vector-transfected cells 
(Figure.4.3.1.B, C). Interestingly, in contrast to wild type Sharp-1, Sharp-1 
SUMO mutant 2KR was unable to inhibit skeletal muscle cell differentiation 
as efficiently as WT Sharp-1 (Figure.4.3.1.B, C). To further validate this 
finding, the expression of muscle differentiation marker troponin T was 
examined. Consistently, troponin T level was reduced in Sharp-1 expressing 
cells, while Sharp-1 2KR expressing cells did not show a significant change in 
the expression of this marker (Figure.4.3.1.D).These morphological and 
molecular evidence suggest that loss of sumoylation enhances the myogenic 
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Figure 4.3.1 Sharp-1 sumoylation modulates its ability to suppress 
myogenesis (A) C2C12 cells were co-transfected with Sharp-1 or Sharp-1 
2KR along with a puromycin resistance vector. Empty vector (pCS2) was 
transfected in control cells. Sharp-1 and Sharp-1 2KR expression was 
determined by western blotting with anti-Myc antibody. (B) MHC staining 
was performed in Sharp-1 and 2KR expressing cells at Day 2 of differentiation 
(C) Myogenic conversion plot. (D) Cell lysates were extracted at Day0, 1 and 




4.3.2 Sharp-1-mediated myogenesis inhibition is SUMO-dependent 
To further confirm that Sharp-1-mediated muscle differentiation inhibition is 
SUMO-dependent, we investigated whether de-sumoylation of Sharp-1 by 
SUMO protease could rescue the morphological changes mediated by Sharp-1 
in myogenesis. The SUMO protease SENP1 was co-transfected with 
equivalent expression levels of Sharp-1 and Sharp-1 2KR in the C2C12 cells 
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(Figure 4.3.2 A). After 2 days in differentiation medium, cells were fixed and 
stained for MHC, a late marker of differentiation predominantly expressed in 
myotubes. As expected, the inhibition of muscle cell differentiation induced 
by Sharp-1 was reversed with the addition of SENP1, while the differentiation 
of Sharp-1 2KR expressing cells was unaltered (Figure 4.3.2.B, C), confirming 
that sumoylation of Sharp-1 is indeed critical in mediating its impact on 
skeletal muscle differentiation. 
 
  




    
 




Figure 4.3.2 Sharp-1 mediated myogenesis inhibition is SUMO-
dependent (A) C2C12 cells were co-transfected with Sharp-1, Sharp-1 2KR, 
SENP1 along with a puromycin resistance vector. Empty vector (pCS2) was 
transfected in control cells. Sharp-1 and Sharp-1 2KR expression was 
determined by western blotting with anti-Myc antibody. (B) MHC staining 
was performed in the cells at Day 2 of differentiation. (C) Myogenic 
conversion plot.  
 
 
4.4   Sumoylated Sharp-1 inhibits MyoD transcriptional activity 
4.4.1  Sharp-1 mediated transcriptional repression is dependent on 
sumoylation.  
It is well known that sumoylation plays critical roles in regulating the 
activities of transcription factors (Gill, 2003). Our earlier studies suggest that 
Sharp-1 inhibits skeletal muscle differentiation through its ability to 
transcriptional repressing MyoD activity (Azmi et al., 2004). To address the 
question whether sumoylation of Sharp-1 is required for transcriptional 
repression, 293T cells were transfected with 9E-TK-Luc (Rossner et al., 2008)  
harboring Sharp-1 binding sites. Consistent with previous reports (Belinda et 
al., 2012a), over-expression of wild type Sharp-1 repressed the reporter 
activity significantly, whereas Sharp-1 2KR was unable to repress the same 












4.4.2   Sharp-1 sumoylation is required for inhibition of MyoD 
transcriptional activity 
MyoD is the master regulator of muscle cell differentiation (Penn et al., 2004). 
Inhibition of myogenesis by over-expression of Sharp-1 is related to reduced 
MyoD transcriptional activity (Azmi et al., 2004). To further explore whether 
Sumoylation of Sharp-1 regulates its ability to regulate MyoD, 10T1/2 cells 
were transfected with pMyog-Luc reporter (Ling et al., 2012a) with MyoD 
alone, or together with Sharp-1 or Sharp-1 2KR. As reported previously (Amzi 
et al., 2004), Sharp-1 significantly repressed MyoD dependent activation of 
pMyog-Luc promoter, whereas the 2KR mutant was less effective than WT 
Sharp-1 in repression of the reporter activity (Figure 4.4.2 A). To further 
confirm this effect, SENP1 was co-transfected along with Sharp-1 and 
luciferase reported assay was performed. As shown in Figure 4.4.2 B, the 
Figure 4.4.1 Sharp-1 mediated transcriptional repression is 
dependent on sumoylation. 293T cells were transfected with 9E-TATA-
Luc promoter (100 ng) along with Sharp-1 (50 ng) or Sharp-1 2KR (50 
ng) as indicated. 48 hours later, cells were harvested and luciferase 
activity was measured. 
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repression on MyoD transcriptional activity by Sharp-1 is reverted in presence 
of SENP1, suggesting that sumoylation affects Sharp-1 mediated repression of 
MyoD transcriptional activity.  
 
 
         
 
     
 
 
Figure 4.4.2 Sharp-1 sumoylation is required for inhibition of MyoD 
transcriptional activity.  (A) 10T1/2 cells were transfected with pMyog-Luc 
promoter (100 ng) together with MyoD (50 ng), Sharp-1 (25/50 ng), Sharp-1 
2KR (50 ng) as indicated. 48 hours later, cells were harvested and assayed for 
luciferase activity. (B) 10T1/2 cells were transfected with pMyog-Luc 
promoter (100 ng) together with MyoD (50 ng), Sharp-1 (25/50 ng), SENP1 




4.5 Sharp-1 mediated transcriptional repression is SUMO- and G9a-
dependent 
Previous studies in our lab demonstrated that Sharp-1 inhibited skeletal muscle 
differentiation and repressed transcriptional activity of MyoD through 
recruitment of the co-repressor G9a (Ling et al., 2012b). To investigate 
whether inhibition of G9a is able to impact the SUMO-dependent 
transcriptional repression of Sharp-1, luciferase reporter assay was performed 
in 10T1/2 cells expressing pMyog-Luc reporter along with MyoD, Sharp-1 
and Sharp-1 2KR. 24 hours later, 0.25 uM UNC0638, a pharmacological 
inhibitor of G9a methyltransferase activity was added. In presence of 
UNC0638, transcriptional repression mediated by Sharp-1 was reversed, 
whereas Sharp-1 2KR mediated repression was not significantly rescued by 



















Figure 4.5 Sharp-1 mediated transcriptional repression is SUMO- and 
G9a-dependent.10T1/2 cells were transfected with pMyog-Luc promoter 
(100 ng) together with MyoD (50 ng), Sharp-1 (50 ng), Sharp-1 2KR (50 ng) 
as indicated. 24 hours after transfection, 0.25 uM UNC0638 was added to cells 
expressing Sharp-1 and Sharp-1 2KR. 24 hours later, cells were harvested and 
analyzed for luciferase activity. 
 
To further address this question whether G9a is involved in SUMO-dependent 
inhibition of myogenesis mediated by Sharp-1, our lab recently demonstrated 
that sumoylation of Sharp-1 was essential for its association with G9a as 
Sharp-1 2KR mutant interacted less efficiently with G9a compared with wild 

































Stra13 and Sharp-1 are basic helix-loop-helix (bHLH) transcription factors 
involved in the control of a lot of complex physiological functions such as 
cellular proliferation and differentiation programs, cell cycle progression, 
immune responses, cancer development, tissue regeneration and circadian 
rhythms (Shen et al., 1997, Sun et al., 2002; Fujimoto et al., 2001; Azmi and 
Taneja, 2002; Azmi et al., 2003). In this study we identified that sumoylation 
was a key modification mechanism for both Stra13 and Sharp-1. As 
established for other transcription factors, these two proteins are sumoylated at 
evolutionarily conserved sites. SUMO-modification significantly affects the 
functions of both proteins. Sumoylation significantly enhances Stra13-
mediated transcriptional repression with an overt impact on its function in cell 
cycle arrest, growth suppression and cellular senescence. Mutating the 
acceptor lysines in Stra13 attenuates the anti-proliferative effect of Stra13, at 
least in part by abrogating its ability to inhibit cyclin D1 expression. Similarly, 
mutation of Sharp-1 SUMO sites abolishes the ability of Sharp-1 to function 
as a transcriptional repressor and a myogenesis inhibitor. The mechanisms of 
repression regulated by sumoylated Stra13 and Sharp-1 in cell growth and 
myogenic differentiation likely involve the SUMO-dependent recruitment of 
two co-repressors HDAC1 and G9a. These studies demonstrate a novel 
mechanism by which transcription factor sumoylation can alter protein-protein 
interactions and bi-potential lineage decisions. 
 
5.1  Sumoylation of Stra13  
Herein, we have demonstrated that Stra13 is sumoylated on the lysine residues 
within the consensus sequence of ψ KXE, which is also located in the 
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transcriptional repression domain (Figure.3.1B and 1C). The lysine residues 
are conserved among Stra13 proteins from human to zebrafish (Figure 3.1A), 
suggesting that other Stra13 proteins are similarly modified, which is 
consistent with the recent report that DEC1, the human homolog of Stra13, is 
sumoylated (Hong et al., 2011). Here, we show that in the presence of 
SUMO1, Stra13 can be efficiently modified in vivo (Figure 3.1B). SUMO 
modification is dynamic and reversed by SUMO protease SENP1 (Figure 
3.1.B). Stra13 is sumoylated predominantly at the more conserved lysine site 
K279 (Figure 3.1.C). Furthermore endogenous Stra13 was found to be 
covalently bound to SUMO after immunoprecipitation (Figure.3.1.5). 
PIAS (protein inhibitor of activated STAT) proteins have been found to 
possess SUMO ligase activity (Kotaja et al., 2002; Sachdev et al., 2001). 
These proteins act as non-enzymatic adaptors to stimulate sumoylation of 
specific targets. We tested PIAS proteins and found that PIAS3 and PIAS1 
were able to enhance the sumoylation of Stra13 and act as the specific E3 
SUMO ligases for Stra13 (Figure 3.1.D) 
 
5.2  Sumoylation is required for growth arrest and senescence mediated 
by Stra13 
Sumoylation has been shown to be a major regulatory modification for many 
protein functions in different manners (Gill, 2004; Girdwood et al., 2004; 
Seeler et al., 2003). Stra13 has been   implicated in several biological 
processes such as cell cycle progression, proliferation, and differentiation and 
transcriptional activity (Sun et al., 2007). Over-expression of Stra13 was 
previously reported to inhibit cell proliferation and cell growth in multiple cell 
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types such as NIH 3T3 (Sun and Taneja, 2000), HEK 293T (Li et al., 2002), 
and HaCat cells (Zawel et al., 2002). Recent studies also demonstrate the 
inverse association of Stra13 with cell proliferation as well as cell invasion 
rate (Bhawal et al., 2011; Qian et al., 2008). Consistent with these 
observations, Stra13 expression is indeed down-regulated in some tumors (Sun 
et al., 2007; Giatromanolaki et al., 2003; Turley et al., 2004). All these studies 
strongly suggested a role of Stra13 as a mediator of cell growth and cell cycle 
progression, and may act as a potential tumor suppressor. However, some 
studies also suggested that Stra13 is over-expressed in many cancers (Sun et 
al., 2007; Chakrabarti et al., 2004; Ivanova et al., 2005; Zhang et al., 2009). 
This seemingly paradoxical functions of Stra13 on cell growth can potentially 
occur by many different causes such as altered sub-cellular localization, or 
association with distinct co-factors in different cell types. Here we present 
evidence in this study that sumoylation, is a post-translational modifications 
involved in this regulation. We found that Stra13-mediated growth 
suppression is SUMO-dependent, as mutating the SUMO sites or over-
expression of SUMO protease SENP1 attenuates its ability to suppress cell 
growth (Figure 3.3.1 & Figure 3.3.2). Interestingly, we observed that SUMO 
conjugation plays critical roles in Stra13-mediated cell cycle arrest (Figure 
3.3.1) and senescence (Figure 3.3.2). Therefore, Stra13 needs to be SUMO 
modified for it to function as a growth suppressor. 
Cyclin D1 plays a crucial role in the progression of the cell cycle from the G1 
to the S phase, and the down-regulation of cyclin D1 leads to G1cell cycle 
arrest (Malumbres et al., 2009; Blain, 2008). Over-expression of Stra13 was 
recently reported to inhibit cyclin D1, suggesting Stra13 may act as a 
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transcriptional repressor of cyclin D1 which correlates with its ability to 
mediate G1 arrest and cause growth suppression Bhawal et al., 2011). 
Consistently, we found enhanced repression of a cyclin D1 promoter 
luciferase reporter with SUMO-conjugated Stra13, while the sumoylation-
deficient mutant Stra13 2KR reduced the transcriptional repression on cyclin 
D1 promoter (Figure 3.4.2), which indicates that sumoylation plays direct 
roles in repression of transcriptional activity. Moreover, SENP1 reverses 
repression mediated by Stra13 WT (Figure 3.4.2).  Furthermore, we observed 
that SUMO conjugated Stra13 was an effective inhibitor of endogenous cyclin 
D1 (Figure 3.4.1A). Another G1/S transition regulator p21, an inhibitor of 
cyclin/cyclin-dependent kinase is able to    initiate growth arrest (Ben-Porath 
et al., 2005). Stra13 has been identified to up-regulate the level of p21 (Xu et 
al., 2012). Consistently, we observed the increased accumulation level of 
endogenous p21 in Stra13 expressing cells, whereas mutation of SUMO 
acceptor lysines abrogated the ability of Stra13 to up-regulate p21 levels 
(Figure 3.4.1). Taken together, these results strongly suggest that the SUMO 
modification is a critical regulatory mechanism for Stra13 to be a 
transcriptional repressor and sumoylation is required for the optimal silencing 
activity of Stra13.  
Senescence is indicated as a tumor-suppression mechanism in some tumor 
types, such as lymphoma, prostate cancer, and benign tumors of melanocytes 
(Bandyopadhya et al., 2007). A growing body of evidence points to a key role 
for sumoylation not only in the regulation of proliferation but also in the 
execution of tumor suppressor responses such as senescence. Li et al. 
demonstrated that over-expression of SUMO-2/3 induced senescence through 
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p53 and retinoblastoma pathways (Li et al., 2006). PIASy, one of the SUMO 
E3 ligases also induced premature senescence, and the fibroblasts lacking 
PIASy exhibited a highly reduced propensity to undergo senescence in 
response to a prosenescence stimulus (Bischof et al., 2006). Interestingly, 
more and more reports showed that Stra13 could induce senescence. The 
oncogene K-rasV12-induced senescence was correlated with Stra13 up-
regulation (Collado et al., 2005). Recent study by Qian et al. suggested that 
over-expression of Stra13 initiated G1 arrest and senescence, and knockdown 
of Stra13 attenuated DNA damage-induced premature senescence (Qian et al., 
2008). Xu et al. reported that over-expression of Stra13 induced cellular 
senescence and inhibited cell growth in cancer cells (Xu et al., 2011). We 
demonstrated that sumoylated Stra13 can stimulate cellular senescence in 
fibroblast cells, as consistent with previous report (Qian et al., 2008; Xu et al., 
2011), whereas, SUMO-deficient mutant Stra13 2KR or the addition of 
SUMO specific protease SENP1 abrogated the ability of Stra13 to induce 
cellular senescence (Figure 3.8.1). Senescence is usually accompanied by 
many changes in gene expression that contributes to the senescence-associated 
phenotypes. It has been shown that p53/p21 and p16 /Rb are the two major 
signaling pathways leading to cellular senescence, thus targeting p53 and p16 
would circumvent oncogenic ras-induced senescence (Serrano et al., 1997). 
Our previous report showed that p53 was activated upon the induction of 
Stra13 (Thin et al., 2007). Stra13 has also been shown to mediate p53-
dependent premature senescence (Qian et al., 2008). Recent study implicateed 
that p21, the mediator of p53 and inhibitor of cyclin/cyclin-dependent kinases, 
was also up-regulated during Stra13-induced senescence (Xu et al., 2011). 
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Here, we demonstrated that senescence induced by Stra13 was accompanied 
by increased expression of p53 and p21, whereas the expression of both 
proteins were diminished in the Stra13 2KR mutant cells, which matched their 
senescence-related phenotypes   (Figure 3.8.3). 
Our data showed no apparent difference in the nuclear localization between 
Stra13 wild type and Stra13 mutants, suggesting that sumoylation of Stra13 
did not affect its sub-cellular localization. Our previous study showed that 
Stra13 repressed transcription through HDAC-dependent mechanism by 
interacting with the C-terminal of HDAC1 (Sun and Taneja, 2000). Many 
other studies also suggest that SUMO conjugation may inhibit transcription by 
mediating the interaction with some co-regulators. For instance, association 
with co-repressors such as HDACs is generally enhanced by sumoyation, and 
conversely interaction with co-activators is reduced (Gill, 2005; Verger et al., 
2003). SUMO-modified proteins can directly recruit HDACs, and association 
with co-repressors such as HDACs is generally enhanced by sumoylation 
(Gill, 2003; Verger, 2003). For example, Yang and Sharrocks previously 
reported that SUMO-modified transcriptional repression of Elk-1 was 
mediated by the recruitment of HDAC2 (Yang et al., 2004). CBP/p300 
transcriptional repression modified by sumoylation resulted from an 
association between p300 and HDAC6 (Girdwood et al., 2003), and 
sumoylated histone H4 recruits HDAC1 and heterochromatin protein1 (HP1) 
(Shiio et al., 2003).  As SUMO sites of Stra13 are located within the HDAC1 
interaction region, we speculated that sumoylation is involved in the 
repressive activity of Stra13 by promoting its interaction with co-repressor 
HDAC1. As previously reported, Stra13 interacted with HDAC1 (Sun and 
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Taneja, 2000), and consistent with a recent report (Xu et al., 2011), our studies 
showed that sumoylation-defective Stra13 mutant interacted less efficiently 
with HDAC1 compared to wild type Stra13 (Figure 3.5A). Furthermore, we 
identified that only sumoylated endogenous Stra13 can associate with HDAC1 
in some Stra13-positive cells (Figure 3.5B-C). These findings suggest that 
sumoylation can play a transient role in the formation of multi-protein 
complexes which is involved in the Stra13-mediated repression of 
transcription activity, and its C-terminal region containing the sumoylation 
sites is an HDAC1-dependent repression domain (Sun and Taneja, 2000). This 
is very similar to the previous report showing that the association between the 
tumor suppressor HIC1 and the class III deacetylase SIRT1 is involved in the 
HIC1-mediated repression (Stankovic-Valentin et al., 2007). Sumoylated 
Stra13 efficiently interacted with HDAC1, whereas the sumoylation defective 
mutant Stra13 2KR exhibited reduced association with HDAC1 (Figure 3.5A). 
These data are consistent with many other studies including MEF2, HIC1 and 
p66α or p66β (Gregoire et al., 2005; Stankovic et al., 2007; Gong et al., 
2006). In these reports, HDACs has also been shown to regulate the 
sumoylation of substrate proteins. In most cases, HDACs enhance 
sumoylation of target proteins such as MEFs and HIC1 that may occur via 
deacetylation of lysine residues, allowing them to be subsequently modified 
by sumoylation (Gregoire et al., 2005; Stankovic-Valentin et al., 2007). 
Intriguingly however, HDAC1 inhibits Stra13 sumoylation and its ability to 
repress cyclin D1 thereby countering its anti-proliferative impact in fibroblast 
cells. HDAC1-mediated inhibition of Stra13 sumoylation and cyclin D1 
repression is consistent with the opposing functions of the two proteins in 
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cellular proliferation. Stra13 has been reported to repress cyclin D1 levels that 
correlate with its ability to mediate G1 arrest. In contrast, HDAC1 and 
HDAC2 promote cellular proliferation and cell cycle progression by inhibiting 
the cyclin dependent kinases (CDK) p21WAF1/CIP1 and p57Kip2 through direct 
regulation of their promoters resulting in transcriptional repression (Lagger et 
al., 2002; Yamaguchi et al., 2010). Correspondingly, mouse embryonic 
fibroblasts lacking HDAC1 and HDAC2 are arrested in G1, and express 
elevated levels p21WAF1/CIP1 and p57Kip2. Moreover, increased expression of 
HDACs has been shown in several cancer cell lines confirming their roles in 
cellular proliferation (Glozak et al., 2007; Marks et al., 2009). Our studies 
suggest that in addition to direct regulation of CDK levels, HDAC1 may 
indirectly enhance proliferation by blocking growth suppressive signals via 
desumoylation of Stra13 relieving repression of cyclin D1. Given the impact 
of HDAC1 activity on Stra13 sumoylation, it is conceivable that in cells that 
over-express both proteins, Stra13 may exist in a desumoylated state, and 
become unable to block cellular proliferation, thereby allowing cells to bypass 
its growth suppressive function. The mechanism by which HDAC1 inhibits 
Stra13 sumoylation remains to be investigated. Since TSA can antagonize the 
effect of HDAC1 on Stra13 sumoylation, endogenous deacetylase activity is 
involved and may reflect a requirement for acetylation-dependent sumoylation 
similar to PML (Hayakawa et al., 2008). Alternatively, histone deacetylation 
by HDAC1 may release promoter bound sumoylated Stra13, which could then 






5.3  Relevance of Sharp-1 sumoylation in skeletal muscle differentiation  
Sharp-1 interacts with MyoD, resulting in the inhibition of its transcriptional 
activity and muscle differentiation (Fujimoto et al., 2001; Azmi and Taneja, 
2002; Azmi et al., 2004). Through this study, we provide the first report that 
Sharp-1 is post-translationally modified by SUMO. We identified the main 
acceptor site for SUMO (lysine240) within the SUMO consensus motif 
(VKQE) in the Sharp-1 sequence which is conserved among different species, 
as conversion of these sites into arginines (R) abolished sumoylation of Sharp-
1 (Figure 4.1.3). Similarly, PIAS family acts as the E3 SUMO ligases for 
Sharp-1.  PIAS3 and PIASxa were shown to stimulate Sharp-1 sumoylation 
(Figure 4.1.4). 
It was reported that protein sumoylation plays a regulatory role in myoblast 
differentiation and was required to regulate the activity of key targets 
downstream of MyoD and myogenin. The overall load of sumoylated proteins 
present in myoblasts diminishes progressively during the progression of 
muscle formation (Riquelme et al., 2006). Consistently, our data showed that 
sumoylation of Sharp-1 was decreased with the process of myoblast 
differentiation (Figure 3.11.5). Over-expression of Sharp-1 was shown to 
inhibit skeletal muscle differentiation and repress myogenic marker gene 
expression (Azmi et al., 2004). We investigated the biological consequences 
of Sharp-1 sumoylation by examining the effect of sumoylation on Sharp-1 
mediated inhibition of myogenesis, and found that mutation of SUMO sites 
abrogates the inhibition effect of Sharp-1 on myogenic differentiation (Figure 
4.3.1). This finding was further confirmed by the addition of SUMO protease 
137 
 
SENP1 which rescued the morphological changes mediated by Sharp-1 in 
myogenesis (Figure 4.3.2). 
SUMO modification of many transcription factors appears to be related with 
transcriptional repression. There are plethora of studies linking SUMO 
modification of key transcriptional repressors and myogenesis such as MSX1, 
MEF2 (Gupta et al., 2006; Wang et al., 2012; Gregoire et al., 2005; Riquelme 
et al., 2006). Sharp-1 has been demonstrated to inhibit myogenesis by 
repressing the transcriptional activity of MyoD (Azmi et al., 2004; Ling et al., 
2012a & 2012b). In our study, it is not surprising to observe that SUMO 
modification is essential to repress the transcriptional activity of MyoD as 
evidenced by the attenuated repression with its mutation (Figure 4.4.2). Our 
study showed a scenario where SUMO modification of repressors of 
differentiation is essential for their repression activity on both transcription 
and myogenesis.  
 
 

























6.1  Conclusions 
Sumoylation plays a significant role in the regulation of transcription factors. 
In this study, we demonstrated that the basic helix-loop-helix transcription 
factors Stra13 and Sharp-1 were SUMO modified at the conserved residues. 
The sumoylation of both Stra13 and Sharp-1 is dynamic and reversed by 
SUMO protease SENP1. Over-expression of the SUMO E3 ligases PIAS3 and 
PIAS1 are shown to enhance Stra13 sumoylation; and PIAS3 and PISAxa can 
act as E3 SUMO ligases to promote the sumoylation of Sharp-1. 
In the first part of this study, we present evidence that SUMO modification 
plays critical roles in mediating biological functions of Stra13. We propose a 
model to summarize the role of sumoylation on mediating Stra13 functions. 
As shown in Figure 6.1.1, we demonstrated that Stra13 sumoylation was 
required for its anti-proliferative effects, as mutation of these target residues, 
or co-expression of the SUMO protease SENP1 with wild type Stra13 
attenuates its functions as a growth suppressor by colony formation assays. 
Furthermore, we identified that sumoylation-dependent colony formation 
reduction upon Stra13 over-expression is due to reduced proliferation rates 
and cell cycle arrest at G1 phase and cell proliferation which are also shown to 
be SUMO-dependent. SUMO-dependent growth suppression mediated by 
Stra13 is not through altering the sub-cellular localization of Stra13, but 
depend on the transcriptional repression of Stra13 on cyclin D1, as we 
observed that Stra13 wild type and mutations show almost identical nuclear 
distribution, whereas Stra13 mutation significantly impairs its ability to 
repress cyclin D1 expression. In addition, mutation of SUMO sites reduces 
association of Stra13 with HDAC1 which plays an essential role in cell cycle 
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progression. HDAC1 inhibits Stra13 sumoylation in a deacetylase-activity 
dependent manner and blocks its anti-proliferative effects. Over-expression of 
HDAC1 can abrogate Stra13-mediated growth suppression by attenuating its 
repression on cyclin D1 promoter in a dose-dependent manner. Moreover, the 
knockdown of HDAC1 markedly promotes the sumoylation of Stra13 and 
augments the Stra13-mediated repression activity of cyclin D1, which further 
confirms the effects of HDAC1 on Stra13-mediated growth inhibition. 
Using SA-β-Galactosidase staining assay, we observed that the cellular 
senescence mediated by Stra13 is also modified by sumoylation as mutation of 
Stra13 or co-expression of the SUMO protease SENP1 with wild type Stra13 
attenuates its ability to induce cellular senescence. Furthermore, we 
demonstrated that Stra13-induced senescence was functioning through the 
regulation of p53/p21 pathway and this regulation is also SUMO-dependent. 
HDAC1 has been shown to be involved in promoting cell proliferation as well 
as cellular senescence, but our results suggest that HDAC1 is not involved in 







Figure 6.1.1 Model showing how SUMO modification regulates Stra13 
functions   Stra13 can be sumoylated by SUMO1. The SUMO ligases PIAS3 
or PIAS1 can enhance sumoylation of Stra13, and the SUMO conjugated form 
of Stra3 can act to repress the expression of cyclin D1 resulting in G1 arrest 
and inhibition of cell proliferation. Sumoylation is also involved in the 
regulation of interaction with HDAC1 and Stra13-mediated cell growth arrest 
and senescence. In addition, SUMO-dependent cell growth arrest mediated by 








In the second part of this study, as shown in Figure 6.1.2, we first reported that 
Sharp-1 is post-translationally modified by SUMO at lysine 240 and 255. 
Furthermore, we demonstrated that sumoylation is involved in Sharp-1 
mediated skeletal muscle differentiation inhibition and transcriptional 
repression, as its ability to act as a repressor is lost when the SUMO acceptor 
sites are mutated. We also indentified that sumoylation of Sharp-1 in skeletal 
muscle cells is significantly reduced upon differentiation. SUMO-dependent 
inhibition of myogenesis is not related to altered nuclear localization, but 
associated with Sharp-1 SUMO-dependent inhibition of MyoD transcriptional 
activity. Our findings reveal a novel role for SUMO modification in 









Figure 6.1.2 Model showing how SUMO modification regulates Shapr-1 
functions   Sharp-1 can be sumoylated by SUMO1. The SUMO ligases PIAS3 
or PIASxa can enhance sumoylation of Sharp-1, and the SUMO conjugated 
form of Sharp-1 can act to repress the activity of myogenic transcription 
factors, therefore leading to the inhibition of skeletal muscle differentiatin.  
 
 
In conclusion, our studies demonstrate sumoylation is an important 
mechanism by which both Stra13 and Sharp-1 transcriptional activity and 
functions are modulated. Our results provide new mechanistic insights into 





6.2   Future studies 
Both Stra13 and Sharp-1 are involved in many biological functions such as 
tissue regeneration, and cellular differentiation programs. How these diverse 
biological responses are regulated remains unclear. It is reported that 
sumoylation plays a critical role in the functions of targeted proteins in vitro, 
also in vivo (Aryaman Shalizi et al., 2006). Since our studies shed light on the 
role of sumoylation in controlling the functional activities of both proteins, 
these studies should provide a platform for future in-depth work to find out if 
sumoylation is involved in other functions of Stra13 and Sharp-1 and 
investigate underlying mechanisms. 
Histone deacetylase (HDAC) inhibitors, a promising class of targeted 
anticancer agents(Glozak et al., 2005). For example, p53 acetylation induced 
by a HDAC inhibitor leads to expression of proapoptotic proteins such as Bax, 
PIG3, and NOXA (Bandyopadhyay et al., 2004; Terui et al., 2003). Increasing 
numbers of proteins have been shown to be targeted by both acetylation and 
sumoylation and this crosstalk between them can efficiently regulate the 
functions of target proteins. The enhanced acetylation by HDAC inhibitor 
TSA leads to increased PML sumoylation and this interplay plays a key role in 
TSA-induced apoptosis (Hayakawa et al., 2008). Acetylation of p53 
antagonized the inhibitory effect of sumoylation on p53 binding to DNA and 
its transcription activity (Wu et al., 2009). Our results suggest that TSA, a 
HDAC inhibitor, can reverse the HDAC1-induced inhibition of Stra13 
sumoylation, and TSA is also able to stimulate the acetylation of sumoylated 
Stra13. It is not known whether acetylation is involved in SUMO-dependent 
transcriptional repression and growth suppression. In addition, Stra13 is 
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known to be down-regulated in some tumors (Sun et al., 2007; Giatromanolaki 
et al., 2003) and its over-expression results in growth suppression, cell cycle 
arrest, and cellular senescence, which are important tumor suppression 
mechanisms (Sun and Taneja, 2000; Beadling et al., 2001; Seimiya et al., 
2002). In our study, we showed that endogenous Stra13 can be sumoylated in 
some Stra13-positive tumor cell lines like MCF7 and K562 (Figure.3.1.5 B-C) 
and this modification is important for its ability to cause growth arrest and 
senescence. However, several tumors show high levels of Stra13. Given that 
our studies show a role for sumoylation in growth suppression, in the future, it 
will be interesting to know 1) Is Stra13 desumoylated involved in tumors 
where it is overexpressed; 2) HDAC1 and its inhibitors also have effects on 
the sumoylation of Stra13 and SUMO- dependent functions in cancer cells or 
tissues. Therefore, further investigation on the effects of sumoylation on tumor 
development is necessary as it will provide a new insight on tumor therapy.  
Our current data suggest that the function of Sharp-1 in myogenesis is SUMO-
dependent. Since Sharp-1 is deregulated in myopathies, it would be very 
interesting to know whether sumoylation of Sharp-1 is associated with its 
deregulation in muscle pathogies. Moreover, our study is largely in vitro, it 
would therefore be important to further explore the roles of sumoylation on the 
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